WO2006040279A1 - Pi3-kinasen - Google Patents
Pi3-kinasen Download PDFInfo
- Publication number
- WO2006040279A1 WO2006040279A1 PCT/EP2005/055015 EP2005055015W WO2006040279A1 WO 2006040279 A1 WO2006040279 A1 WO 2006040279A1 EP 2005055015 W EP2005055015 W EP 2005055015W WO 2006040279 A1 WO2006040279 A1 WO 2006040279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- optionally substituted
- methyl
- het
- Prior art date
Links
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title claims abstract description 23
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 17
- 230000000172 allergic effect Effects 0.000 claims abstract description 12
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 10
- 208000026935 allergic disease Diseases 0.000 claims abstract description 9
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 230000001363 autoimmune Effects 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 210000002850 nasal mucosa Anatomy 0.000 claims abstract description 5
- 208000017520 skin disease Diseases 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 508
- -1 het Chemical group 0.000 claims description 402
- 229910052799 carbon Inorganic materials 0.000 claims description 296
- 229910052739 hydrogen Inorganic materials 0.000 claims description 222
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 201
- 125000003118 aryl group Chemical group 0.000 claims description 151
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 125
- 125000001072 heteroaryl group Chemical group 0.000 claims description 125
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 98
- 150000003839 salts Chemical class 0.000 claims description 85
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 79
- 229910052757 nitrogen Inorganic materials 0.000 claims description 79
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 72
- 150000004677 hydrates Chemical class 0.000 claims description 71
- 239000012453 solvate Substances 0.000 claims description 71
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 70
- 229910052736 halogen Inorganic materials 0.000 claims description 68
- 150000002367 halogens Chemical class 0.000 claims description 62
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 61
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 59
- 239000000460 chlorine Substances 0.000 claims description 57
- 125000004432 carbon atom Chemical group C* 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 50
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 43
- 125000000304 alkynyl group Chemical group 0.000 claims description 42
- 125000003003 spiro group Chemical group 0.000 claims description 42
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 41
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 38
- 229910052801 chlorine Inorganic materials 0.000 claims description 32
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 32
- 125000005842 heteroatom Chemical group 0.000 claims description 29
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 27
- 229910052794 bromium Inorganic materials 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 239000011593 sulfur Substances 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- 125000002947 alkylene group Chemical group 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 21
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 20
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 11
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 claims description 10
- 206010006451 bronchitis Diseases 0.000 claims description 10
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 9
- 125000002541 furyl group Chemical group 0.000 claims description 9
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 8
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 7
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 6
- 125000005622 butynylene group Chemical group 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 206010001889 Alveolitis Diseases 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 208000000592 Nasal Polyps Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
- 125000004419 alkynylene group Chemical group 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000005333 pulmonary edema Diseases 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010052613 Allergic bronchitis Diseases 0.000 claims description 2
- 206010049153 Allergic sinusitis Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010015218 Erythema multiforme Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000006311 Pyoderma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 208000029771 childhood onset asthma Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 208000024963 hair loss Diseases 0.000 claims description 2
- 230000003676 hair loss Effects 0.000 claims description 2
- 244000000013 helminth Species 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 201000006334 interstitial nephritis Diseases 0.000 claims description 2
- 239000002085 irritant Substances 0.000 claims description 2
- 231100000021 irritant Toxicity 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 206010003504 Aspiration Diseases 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 208000031973 Conjunctivitis infective Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 102200012531 rs111033829 Human genes 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 abstract description 3
- 210000005095 gastrointestinal system Anatomy 0.000 abstract 1
- 230000003137 locomotive effect Effects 0.000 abstract 1
- 230000004526 pharmaceutical effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 301
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 192
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 122
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 110
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 239000000243 solution Substances 0.000 description 91
- 239000011541 reaction mixture Substances 0.000 description 86
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 78
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- 239000012074 organic phase Substances 0.000 description 64
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000002244 precipitate Substances 0.000 description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 34
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 33
- 238000001816 cooling Methods 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 30
- 239000002253 acid Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 26
- 239000000725 suspension Substances 0.000 description 25
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- 238000010992 reflux Methods 0.000 description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 150000002148 esters Chemical group 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 16
- 229960000583 acetic acid Drugs 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 229910000027 potassium carbonate Inorganic materials 0.000 description 15
- 235000011181 potassium carbonates Nutrition 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- ADODRSVGNHNKAT-UHFFFAOYSA-N 2-Chlorophenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1Cl ADODRSVGNHNKAT-UHFFFAOYSA-N 0.000 description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
- 239000012452 mother liquor Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000012362 glacial acetic acid Substances 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 11
- 229920002261 Corn starch Polymers 0.000 description 11
- 239000000808 adrenergic beta-agonist Substances 0.000 description 11
- 230000003454 betamimetic effect Effects 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 11
- 239000008120 corn starch Substances 0.000 description 11
- 229940099112 cornstarch Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 0 CCC(C)(C)C(N(*)*)=O Chemical compound CCC(C)(C)C(N(*)*)=O 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 9
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 229940125773 compound 10 Drugs 0.000 description 7
- 239000008298 dragée Substances 0.000 description 7
- 229940121647 egfr inhibitor Drugs 0.000 description 7
- 229960004198 guanidine Drugs 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 7
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 150000003842 bromide salts Chemical class 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LJNCITYJAYDQEV-UHFFFAOYSA-N methyl 3-chloro-4-hydrazinylbenzoate Chemical compound COC(=O)C1=CC=C(NN)C(Cl)=C1 LJNCITYJAYDQEV-UHFFFAOYSA-N 0.000 description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 4
- ZDHRRHRWHFBMQV-UHFFFAOYSA-N 4-(dibenzylamino)cyclohexan-1-one Chemical compound C1CC(=O)CCC1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 ZDHRRHRWHFBMQV-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- YZPSRQSRPXVVQI-MXVIHJGJSA-N C1C[C@@H](N)CC[C@@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 Chemical compound C1C[C@@H](N)CC[C@@H]1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 YZPSRQSRPXVVQI-MXVIHJGJSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 3
- LWMPFIOTEAXAGV-UHFFFAOYSA-N NN1CCCCC1 Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 3
- FPTCVTJCJMVIDV-UHFFFAOYSA-N NNC(Cc1ccccc1)=O Chemical compound NNC(Cc1ccccc1)=O FPTCVTJCJMVIDV-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IGCVAKMLNISJHR-UHFFFAOYSA-N n-methylpiperidin-1-amine Chemical compound CNN1CCCCC1 IGCVAKMLNISJHR-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- FGZHEMUBCFDEDD-UHFFFAOYSA-N 1-imidazol-1-yl-2-methoxyethanone Chemical compound COCC(=O)N1C=CN=C1 FGZHEMUBCFDEDD-UHFFFAOYSA-N 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 2
- YKZXWNCXGVYCKF-UHFFFAOYSA-N 2,2-bis(4-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C=CC=1C(O)(C(=O)O)C1=CC=C(F)C=C1 YKZXWNCXGVYCKF-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- ZMPRRFPMMJQXPP-UHFFFAOYSA-N 2-sulfobenzoic acid Chemical class OC(=O)C1=CC=CC=C1S(O)(=O)=O ZMPRRFPMMJQXPP-UHFFFAOYSA-N 0.000 description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
- ULMFXAMQUGLVGA-LJQANCHMSA-N 3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-n-[(2r)-4,4,4-trifluoro-2-methylbutyl]indole-5-carboxamide Chemical compound C=1C=C(CC=2C3=CC(=CC=C3N(C)C=2)C(=O)NC[C@H](C)CC(F)(F)F)C(OC)=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C ULMFXAMQUGLVGA-LJQANCHMSA-N 0.000 description 2
- NMGODFWGUBLTTA-UHFFFAOYSA-N 3-amino-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(N)C(=O)NC2=C1 NMGODFWGUBLTTA-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BGXQRDRUCGIGKN-UHFFFAOYSA-N 4-(4-nitrophenyl)piperidine;hydrochloride Chemical compound Cl.C1=CC([N+](=O)[O-])=CC=C1C1CCNCC1 BGXQRDRUCGIGKN-UHFFFAOYSA-N 0.000 description 2
- IWLZUBOGRKFSDF-UHFFFAOYSA-N 4-(7-acetamido-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-1-yl)benzoic acid Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C=NN1C1=CC=C(C(O)=O)C=C1 IWLZUBOGRKFSDF-UHFFFAOYSA-N 0.000 description 2
- CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- GLDKOUIXUKVODH-UHFFFAOYSA-N 7-(cyclopropylmethoxy)quinazoline Chemical compound C=1C=C2C=NC=NC2=CC=1OCC1CC1 GLDKOUIXUKVODH-UHFFFAOYSA-N 0.000 description 2
- PYUGFOWNYMLROI-KPKJPENVSA-N 8-[(e)-2-[4-[4-(4-fluorophenyl)butoxy]phenyl]ethenyl]-2-(2h-tetrazol-5-yl)chromen-4-one Chemical compound C1=CC(F)=CC=C1CCCCOC(C=C1)=CC=C1\C=C\C1=CC=CC2=C1OC(C=1NN=NN=1)=CC2=O PYUGFOWNYMLROI-KPKJPENVSA-N 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ANFOHIPXDYAFJO-UHFFFAOYSA-N N-[1-(2-chlorophenyl)-3-(1H-imidazol-5-yl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C=2N=CNC=2)=NN1C1=CC=CC=C1Cl ANFOHIPXDYAFJO-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- BCIIMDOZSUCSEN-UHFFFAOYSA-N NC1CCNCC1 Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 2
- VMFUMDXVTKTZQY-UHFFFAOYSA-N NNC(c1c(cccc2)c2ccc1)=O Chemical compound NNC(c1c(cccc2)c2ccc1)=O VMFUMDXVTKTZQY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- JSWQDLBFVSTSIW-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine Chemical compound NNC1=CC=CC=C1C(F)(F)F JSWQDLBFVSTSIW-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- ULPBQRNXCIKBIJ-UHFFFAOYSA-N n,n-dibenzyl-4-morpholin-4-ylcyclohexan-1-amine Chemical compound C=1C=CC=CC=1CN(C1CCC(CC1)N1CCOCC1)CC1=CC=CC=C1 ULPBQRNXCIKBIJ-UHFFFAOYSA-N 0.000 description 2
- FSDOTMQXIKBFKJ-UHFFFAOYSA-N n-(2,5-dichloropyridin-3-yl)-8-methoxyquinoline-5-carboxamide Chemical compound C12=CC=CN=C2C(OC)=CC=C1C(=O)NC1=CC(Cl)=CN=C1Cl FSDOTMQXIKBFKJ-UHFFFAOYSA-N 0.000 description 2
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 2
- LQHFMOLYVYXOPJ-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-3-(furan-3-yl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C2=COC=C2)=NN1C1=CC=CC=C1Cl LQHFMOLYVYXOPJ-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 125000005547 pivalate group Chemical group 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- UNRBEYYLYRXYCG-UHFFFAOYSA-N (1-ethylpyrrolidin-2-yl)methanamine Chemical compound CCN1CCCC1CN UNRBEYYLYRXYCG-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- DVCFNCQPOANJGU-BYPYZUCNSA-N (2s)-oxolane-2-carbonyl chloride Chemical compound ClC(=O)[C@@H]1CCCO1 DVCFNCQPOANJGU-BYPYZUCNSA-N 0.000 description 1
- YQVZREHUWCCHHX-UHFFFAOYSA-N (4-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Cl)C=C1 YQVZREHUWCCHHX-UHFFFAOYSA-N 0.000 description 1
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 1
- HMHWNJGOHUYVMD-UHFFFAOYSA-N (4-methylanilino)azanium;chloride Chemical compound Cl.CC1=CC=C(NN)C=C1 HMHWNJGOHUYVMD-UHFFFAOYSA-N 0.000 description 1
- XTNYQMSCYWBFJX-KRWDZBQOSA-N (4r)-1-[(4-bromophenyl)methyl]-4-(2-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound C([C@H](CC1=O)C2=CC=C(C=C2OC2CCCC2)OC)N1CC1=CC=C(Br)C=C1 XTNYQMSCYWBFJX-KRWDZBQOSA-N 0.000 description 1
- JJGFAXYGLYUHIN-UHFFFAOYSA-N (5-fluoro-2-methylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC1=CC=C(F)C=C1N[NH3+] JJGFAXYGLYUHIN-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- LUOSNGFOANFUES-UHFFFAOYSA-N 1-(2,2,2-trifluoroacetyl)piperidin-4-one Chemical compound FC(F)(F)C(=O)N1CCC(=O)CC1 LUOSNGFOANFUES-UHFFFAOYSA-N 0.000 description 1
- FJROBTIRRFPVEC-UHFFFAOYSA-N 1-(4-aminobut-2-ynyl)-3-(1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)urea Chemical compound C1=2C=3SC(NC(=O)NCC#CCN)=NC=3CCC=2C=NN1C1=CC=CC=C1 FJROBTIRRFPVEC-UHFFFAOYSA-N 0.000 description 1
- CVTOUNWGORDQGR-UHFFFAOYSA-N 1-(cyclopropylmethyl)-4-(4-nitrophenyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1CCN(CC2CC2)CC1 CVTOUNWGORDQGR-UHFFFAOYSA-N 0.000 description 1
- IVLIBVDZIYFXBZ-UHFFFAOYSA-N 1-(cyclopropylmethyl)piperazine Chemical compound C1CNCCN1CC1CC1 IVLIBVDZIYFXBZ-UHFFFAOYSA-N 0.000 description 1
- FGRIVGLVHHUSHB-UHFFFAOYSA-N 1-(cyclopropylmethyl)piperidine Chemical compound C1CCCCN1CC1CC1 FGRIVGLVHHUSHB-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- WBOMXUMQOVQNKT-UHFFFAOYSA-N 1-bromo-3-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=CC(Br)=C1 WBOMXUMQOVQNKT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- SIACYUBAVVFJSK-UHFFFAOYSA-N 1-imidazol-1-yl-2-methylpropan-1-one Chemical compound CC(C)C(=O)N1C=CN=C1 SIACYUBAVVFJSK-UHFFFAOYSA-N 0.000 description 1
- 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006021 1-methyl-2-propenyl group Chemical group 0.000 description 1
- GZNDUKANJZIZOT-UHFFFAOYSA-N 1-methyl-4-(4-nitrophenyl)piperazine Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C=C1 GZNDUKANJZIZOT-UHFFFAOYSA-N 0.000 description 1
- UQCPWYKIUXJDQV-UHFFFAOYSA-N 1-methyl-4-(4-nitrophenyl)piperidine Chemical compound C1CN(C)CCC1C1=CC=C([N+]([O-])=O)C=C1 UQCPWYKIUXJDQV-UHFFFAOYSA-N 0.000 description 1
- WZTRQGJMMHMFGH-UHFFFAOYSA-N 1-methyl-imidazole-4-carboxylic acid Chemical compound CN1C=NC(C(O)=O)=C1 WZTRQGJMMHMFGH-UHFFFAOYSA-N 0.000 description 1
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- ZZAKLGGGMWORRT-UHFFFAOYSA-N 1-methylsulfonylpiperazine Chemical compound CS(=O)(=O)N1CCNCC1 ZZAKLGGGMWORRT-UHFFFAOYSA-N 0.000 description 1
- XLQINJMEQSAESU-UHFFFAOYSA-N 1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-amine Chemical compound C1=2C=3SC(N)=NC=3CCC=2C=NN1C1=CC=CC=C1 XLQINJMEQSAESU-UHFFFAOYSA-N 0.000 description 1
- WZBDFCFLBILPBP-UHFFFAOYSA-N 1-phenyl-4h-pyrazolo[2,3]cyclopenta[2,4-b][1,3]thiazol-6-amine Chemical compound C1=2C=3SC(N)=NC=3CC=2C=NN1C1=CC=CC=C1 WZBDFCFLBILPBP-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
- QKXNHFFCIYENOO-UHFFFAOYSA-N 16-thia-2,4,5,8-tetrazatetracyclo[8.6.0.02,6.011,15]hexadeca-1(10),3,5,8,11(15),13-hexaene Chemical compound C1=NCC2=NN=CN2C(S2)=C1C1=C2C=CC1 QKXNHFFCIYENOO-UHFFFAOYSA-N 0.000 description 1
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 description 1
- FSLXROAVEZTTJV-UHFFFAOYSA-N 2,2,2-trifluoro-1-(4-phenylpiperidin-1-yl)ethanone Chemical compound C1CN(C(=O)C(F)(F)F)CCC1C1=CC=CC=C1 FSLXROAVEZTTJV-UHFFFAOYSA-N 0.000 description 1
- RTZBQWADJQLQHG-UHFFFAOYSA-N 2,2,2-trifluoro-1-[4-(4-nitrophenyl)piperidin-1-yl]ethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1CCN(C(=O)C(F)(F)F)CC1 RTZBQWADJQLQHG-UHFFFAOYSA-N 0.000 description 1
- ODTCIQJQWXLXQO-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-1-(4-hydrazinylpiperidin-1-yl)ethanone Chemical compound OC(=O)C(F)(F)F.NNC1CCN(C(=O)C(F)(F)F)CC1 ODTCIQJQWXLXQO-UHFFFAOYSA-N 0.000 description 1
- ZMXHONJJTQSZKY-UHFFFAOYSA-N 2,2-bis(3,4-difluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C(F)=CC=1C(O)(C(=O)O)C1=CC=C(F)C(F)=C1 ZMXHONJJTQSZKY-UHFFFAOYSA-N 0.000 description 1
- AOPATQAZIRXNOX-UHFFFAOYSA-N 2-(1-methylcyclopropyl)acetic acid Chemical compound OC(=O)CC1(C)CC1 AOPATQAZIRXNOX-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- CSEWAUGPAQPMDC-UHFFFAOYSA-N 2-(4-aminophenyl)acetic acid Chemical compound NC1=CC=C(CC(O)=O)C=C1 CSEWAUGPAQPMDC-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- DRDJPBASWGLGOR-UHFFFAOYSA-N 2-[(1-ethylpyrrolidin-2-yl)methylamino]-n-(1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound CCN1CCCC1CNCC(=O)NC(S1)=NC2=C1C(N(N=C1)C=3C=CC=CC=3)=C1CC2 DRDJPBASWGLGOR-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YWIZTPKVSNXXRX-UHFFFAOYSA-N 2-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]acetamide Chemical compound C=12C=C(OC3CCN(CC(N)=O)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YWIZTPKVSNXXRX-UHFFFAOYSA-N 0.000 description 1
- NAPHCSBIOIUGPK-LLVKDONJSA-N 2-[[(2r)-oxolan-2-yl]methoxy]quinazoline Chemical compound N=1C=C2C=CC=CC2=NC=1OC[C@H]1CCCO1 NAPHCSBIOIUGPK-LLVKDONJSA-N 0.000 description 1
- NAPHCSBIOIUGPK-NSHDSACASA-N 2-[[(2s)-oxolan-2-yl]methoxy]quinazoline Chemical compound N=1C=C2C=CC=CC2=NC=1OC[C@@H]1CCCO1 NAPHCSBIOIUGPK-NSHDSACASA-N 0.000 description 1
- ODELOHGYKTYWQO-UHFFFAOYSA-N 2-amino-n-(1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)CN)=NC=3CCC=2C=NN1C1=CC=CC=C1 ODELOHGYKTYWQO-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- ROZCQYLERXSBBC-UHFFFAOYSA-N 2-bromocyclopentane-1,3-dione Chemical compound BrC1C(=O)CCC1=O ROZCQYLERXSBBC-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- CIOUWZMKJGQFFL-UHFFFAOYSA-N 2-carbamimidoylbenzoic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.NC(=N)C1=CC=CC=C1C(O)=O CIOUWZMKJGQFFL-UHFFFAOYSA-N 0.000 description 1
- JVGPNAUCOPHMSN-UHFFFAOYSA-N 2-chloro-4-hydrazinylphenol Chemical compound NNC1=CC=C(O)C(Cl)=C1 JVGPNAUCOPHMSN-UHFFFAOYSA-N 0.000 description 1
- MXVMRHIWTSFDPU-UHFFFAOYSA-N 2-chlorobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC=C1Cl MXVMRHIWTSFDPU-UHFFFAOYSA-N 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- KFGVDCBVGNMCJC-UHFFFAOYSA-N 2-hydrazinylbenzoic acid Chemical compound NNC1=CC=CC=C1C(O)=O KFGVDCBVGNMCJC-UHFFFAOYSA-N 0.000 description 1
- FYBWCFWHARETCC-UHFFFAOYSA-N 2-hydroxy-n-(1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)CO)=NC=3CCC=2C=NN1C1=CC=CC=C1 FYBWCFWHARETCC-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- IMBNEKOMEDCTCL-UHFFFAOYSA-N 2-methyl-1-piperidin-1-ylpropan-2-amine Chemical compound CC(C)(N)CN1CCCCC1 IMBNEKOMEDCTCL-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- FGLBSLMDCBOPQK-UHFFFAOYSA-N 2-nitropropane Chemical compound CC(C)[N+]([O-])=O FGLBSLMDCBOPQK-UHFFFAOYSA-N 0.000 description 1
- DBCKRBGYGMVSTI-UHFFFAOYSA-N 2-oxo-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]ethylazaniumyl]ethyl]-3h-1,3-benzothiazol-4-olate Chemical compound C1=2SC(=O)NC=2C(O)=CC=C1CCNCCS(=O)(=O)CCCOCCC1=CC=CC=C1 DBCKRBGYGMVSTI-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 description 1
- KHXXMSARUQULRI-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-4-(difluoromethoxy)benzamide Chemical compound ClC1=CN(O)C=C(Cl)C1=NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 KHXXMSARUQULRI-UHFFFAOYSA-N 0.000 description 1
- JOBPGDXYRPFRIV-UHFFFAOYSA-N 3-amino-5-chlorophenol Chemical compound NC1=CC(O)=CC(Cl)=C1 JOBPGDXYRPFRIV-UHFFFAOYSA-N 0.000 description 1
- AJKDUJRRWLQXHM-UHFFFAOYSA-N 3-bromocyclohexene Chemical compound BrC1CCCC=C1 AJKDUJRRWLQXHM-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- IPEATTYBFBRNEB-UHFFFAOYSA-N 3-trimethylsilylprop-2-ynoic acid Chemical compound C[Si](C)(C)C#CC(O)=O IPEATTYBFBRNEB-UHFFFAOYSA-N 0.000 description 1
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 description 1
- HQQCRVHZMQHQOA-UHFFFAOYSA-N 4,4-dimethylpiperidine;hydrochloride Chemical compound [Cl-].CC1(C)CC[NH2+]CC1 HQQCRVHZMQHQOA-UHFFFAOYSA-N 0.000 description 1
- SWNLVRBFNUXRMQ-UHFFFAOYSA-N 4-(4,4-dimethylpiperidin-1-yl)cyclohexan-1-amine Chemical compound C1CC(C)(C)CCN1C1CCC(N)CC1 SWNLVRBFNUXRMQ-UHFFFAOYSA-N 0.000 description 1
- MOZNZNKHRXRLLF-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1 MOZNZNKHRXRLLF-UHFFFAOYSA-N 0.000 description 1
- MRHJLNHIRRALBT-UHFFFAOYSA-N 4-(4-phenylpiperazin-1-yl)cyclohexan-1-amine Chemical compound C1CC(N)CCC1N1CCN(C=2C=CC=CC=2)CC1 MRHJLNHIRRALBT-UHFFFAOYSA-N 0.000 description 1
- PLHHWRFVKOIFNG-UHFFFAOYSA-N 4-(5,5-dimethyl-2-oxomorpholin-4-yl)-n-[4-(3-ethynylanilino)quinazolin-6-yl]but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC1=CC=C(N=CN=C2NC=3C=C(C=CC=3)C#C)C2=C1 PLHHWRFVKOIFNG-UHFFFAOYSA-N 0.000 description 1
- MCIHSGCVYHIJLQ-UHFFFAOYSA-N 4-(7-acetamido-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-1-yl)benzenesulfonic acid Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C=NN1C1=CC=C(S(O)(=O)=O)C=C1 MCIHSGCVYHIJLQ-UHFFFAOYSA-N 0.000 description 1
- QNGKSYLFCYIUAV-UHFFFAOYSA-N 4-(dimethylamino)-n-(1-phenyl-4h-pyrazolo[2,3]cyclopenta[2,4-b][1,3]thiazol-6-yl)butanamide Chemical compound C1=2C=3SC(NC(=O)CCCN(C)C)=NC=3CC=2C=NN1C1=CC=CC=C1 QNGKSYLFCYIUAV-UHFFFAOYSA-N 0.000 description 1
- LRGHHVXWOZHPJF-UHFFFAOYSA-N 4-(dimethylamino)butanoyl chloride Chemical compound CN(C)CCCC(Cl)=O LRGHHVXWOZHPJF-UHFFFAOYSA-N 0.000 description 1
- BAVSOHJMQHHWFH-UHFFFAOYSA-N 4-(dimethylamino)butanoyl chloride;hydrochloride Chemical compound Cl.CN(C)CCCC(Cl)=O BAVSOHJMQHHWFH-UHFFFAOYSA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- LIXBJWRFCNRAPA-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-UHFFFAOYSA-N 0.000 description 1
- DAIBLUSVAFXMJJ-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxyethyl]-6,6-dimethylmorpholin-2-one Chemical compound C=12C=C(OCCN3CC(C)(C)OC(=O)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 DAIBLUSVAFXMJJ-UHFFFAOYSA-N 0.000 description 1
- QJARANVHKUKWBO-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-3-fluorophenol;4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-2-[(4-methoxyphenyl)methylamino]phenol Chemical compound C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C1=CC=C(O)C=C1F.C1=CC(OC)=CC=C1CNC1=CC(C(O)CNC(C)(C)CCN2C3=CC=CC=C3N=C2)=CC=C1O QJARANVHKUKWBO-UHFFFAOYSA-N 0.000 description 1
- DYJUTMKGOQMFFN-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-(2-methoxyethyl)-n-methylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)N(C)CCOC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 DYJUTMKGOQMFFN-UHFFFAOYSA-N 0.000 description 1
- KJGKVANCDSTYDH-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxy-n-(3-methoxypropyl)piperidine-1-carboxamide Chemical compound C1CN(C(=O)NCCCOC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 KJGKVANCDSTYDH-UHFFFAOYSA-N 0.000 description 1
- JAFDYPYUQHLWBH-UHFFFAOYSA-N 4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidine-1-carbonitrile Chemical compound C=12C=C(OC3CCN(CC3)C#N)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 JAFDYPYUQHLWBH-UHFFFAOYSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- QMYRXIWINUJUNY-UHFFFAOYSA-N 4-[6,7-diethoxy-2,3-bis(hydroxymethyl)naphthalen-1-yl]-1-(2-methoxyethyl)pyridin-2-one Chemical compound C=12C=C(OCC)C(OCC)=CC2=CC(CO)=C(CO)C=1C=1C=CN(CCOC)C(=O)C=1 QMYRXIWINUJUNY-UHFFFAOYSA-N 0.000 description 1
- QDNYVRADQFGILN-UHFFFAOYSA-N 4-[7-acetamido-3-(methoxymethyl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-1-yl]-3-chloro-n-(1-methylpiperidin-4-yl)benzamide Chemical compound C1CC=2N=C(NC(C)=O)SC=2C2=C1C(COC)=NN2C(C(=C1)Cl)=CC=C1C(=O)NC1CCN(C)CC1 QDNYVRADQFGILN-UHFFFAOYSA-N 0.000 description 1
- ZYZQSCWSPFLAFM-UHFFFAOYSA-N 4-amino-2-chlorophenol Chemical compound NC1=CC=C(O)C(Cl)=C1 ZYZQSCWSPFLAFM-UHFFFAOYSA-N 0.000 description 1
- PHXGKHTWEOPCEW-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)aniline Chemical compound NC1=CC=C(Br)C=C1C(F)(F)F PHXGKHTWEOPCEW-UHFFFAOYSA-N 0.000 description 1
- CFBUZOUXXHZCFB-UHFFFAOYSA-N 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-cyclohexanecarboxylic acid Chemical compound COC1=CC=C(C2(CCC(CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YZPSRQSRPXVVQI-UHFFFAOYSA-N 4-n,4-n-dibenzylcyclohexane-1,4-diamine Chemical compound C1CC(N)CCC1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 YZPSRQSRPXVVQI-UHFFFAOYSA-N 0.000 description 1
- KMVPXBDOWDXXEN-UHFFFAOYSA-N 4-nitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1 KMVPXBDOWDXXEN-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- CFRUILQUHZWJIG-UHFFFAOYSA-N 4-piperidin-1-ylcyclohexan-1-amine Chemical compound C1CC(N)CCC1N1CCCCC1 CFRUILQUHZWJIG-UHFFFAOYSA-N 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- CBQAJPUQRCULHM-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one;6-hydroxy-8-[1-hydroxy-2-[[1-(4-hydroxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1.C=1C(O)=CC=2NC(=O)COC=2C=1C(O)CNC(C)(C)CC1=CC=C(O)C=C1 CBQAJPUQRCULHM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- ZLLOWHFKKIOINR-UHFFFAOYSA-N 5-phenyl-1,3-thiazole Chemical class S1C=NC=C1C1=CC=CC=C1 ZLLOWHFKKIOINR-UHFFFAOYSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- CHEQBVNZCTZXHB-UHFFFAOYSA-N 7-acetamido-1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazole-3-carboxylic acid Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C(O)=O)=NN1C1=CC=CC=C1 CHEQBVNZCTZXHB-UHFFFAOYSA-N 0.000 description 1
- BIZFHQDZRNKNAU-UHFFFAOYSA-N 7-nitro-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC([N+](=O)[O-])=CC=C21 BIZFHQDZRNKNAU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- JALKRHQYYXOVJR-UHFFFAOYSA-N 8-[2-[[1-(4-ethoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-6-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound C1=CC(OCC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 JALKRHQYYXOVJR-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZNSMNVMLTJELDZ-UHFFFAOYSA-N Bis(2-chloroethyl)ether Chemical compound ClCCOCCCl ZNSMNVMLTJELDZ-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- RMFVVPBBEDMZQI-UHFFFAOYSA-N C(CC1)Cc2c1[s]cn2 Chemical compound C(CC1)Cc2c1[s]cn2 RMFVVPBBEDMZQI-UHFFFAOYSA-N 0.000 description 1
- KFOAQYYCEAGMEF-UHFFFAOYSA-N C(CNC1)c2c1[nH]nc2 Chemical compound C(CNC1)c2c1[nH]nc2 KFOAQYYCEAGMEF-UHFFFAOYSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N C(CNC1)c2c1cccc2 Chemical compound C(CNC1)c2c1cccc2 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- URMVFILWXLQJIP-UHFFFAOYSA-N C(CNC1)c2c1nc[nH]2 Chemical compound C(CNC1)c2c1nc[nH]2 URMVFILWXLQJIP-UHFFFAOYSA-N 0.000 description 1
- DHLNJCDNXLGOMC-RQNOJGIXSA-N C(N(Cc1ccccc1)[C@H]1CC[C@@H](CC1)N1CCCC1)c1ccccc1 Chemical compound C(N(Cc1ccccc1)[C@H]1CC[C@@H](CC1)N1CCCC1)c1ccccc1 DHLNJCDNXLGOMC-RQNOJGIXSA-N 0.000 description 1
- BGUVNTGEVJOZHY-SOAUALDESA-N C(N(Cc1ccccc1)[C@H]1CC[C@@H](CC1)N1CCCCC1)c1ccccc1 Chemical compound C(N(Cc1ccccc1)[C@H]1CC[C@@H](CC1)N1CCCCC1)c1ccccc1 BGUVNTGEVJOZHY-SOAUALDESA-N 0.000 description 1
- RLSAIUMSBODSSZ-WXUXXXNLSA-N C(N(Cc1ccccc1)[C@H]1CC[C@@H](CC1)N1CCN(CC1)c1ccccc1)c1ccccc1 Chemical compound C(N(Cc1ccccc1)[C@H]1CC[C@@H](CC1)N1CCN(CC1)c1ccccc1)c1ccccc1 RLSAIUMSBODSSZ-WXUXXXNLSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QGBIFMJAQARMNQ-QISPFCDLSA-N C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(SC)[C@@]2(C)C[C@@H]1O QGBIFMJAQARMNQ-QISPFCDLSA-N 0.000 description 1
- KGEDETVMWLCPSA-CALCHBBNSA-N C1C[C@H](N(C)C(=O)COC)CC[C@@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 Chemical compound C1C[C@H](N(C)C(=O)COC)CC[C@@H]1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=C(F)C(Cl)=C1 KGEDETVMWLCPSA-CALCHBBNSA-N 0.000 description 1
- LCVXWZSYIUNUJR-BGYRXZFFSA-N C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)C(=O)C3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)C(=O)C3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LCVXWZSYIUNUJR-BGYRXZFFSA-N 0.000 description 1
- FPTTXLPPNCBKID-CALCHBBNSA-N C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)C(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)C(C)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 FPTTXLPPNCBKID-CALCHBBNSA-N 0.000 description 1
- PEHNBYTXRHCHKF-IYBDPMFKSA-N C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 Chemical compound C=12C=C(O[C@@H]3CC[C@@H](CC3)N(C)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 PEHNBYTXRHCHKF-IYBDPMFKSA-N 0.000 description 1
- VYYQHJQFEIAOJQ-UHFFFAOYSA-N CC(C)(C)NC(NCC#CCNC(Nc1nc(CCc2c-3[n](-c4ccccc4)nc2)c-3[s]1)=O)=O Chemical compound CC(C)(C)NC(NCC#CCNC(Nc1nc(CCc2c-3[n](-c4ccccc4)nc2)c-3[s]1)=O)=O VYYQHJQFEIAOJQ-UHFFFAOYSA-N 0.000 description 1
- JCXYZQUYVNLCTG-UHFFFAOYSA-N CC(C)(CN1CCOCC1)N Chemical compound CC(C)(CN1CCOCC1)N JCXYZQUYVNLCTG-UHFFFAOYSA-N 0.000 description 1
- DVZOAKYOSURPHW-UHFFFAOYSA-N CC(Nc1nc(CCC(C(c2c[n](COCC[Si](C)(C)C)cn2)=O)C2=O)c2[s]1)=O Chemical compound CC(Nc1nc(CCC(C(c2c[n](COCC[Si](C)(C)C)cn2)=O)C2=O)c2[s]1)=O DVZOAKYOSURPHW-UHFFFAOYSA-N 0.000 description 1
- PBTKWUDQWQBJCK-UHFFFAOYSA-N CC(Nc1nc(CCc2c(-c3c[o]cc3)[n](-c(cccc3)c3Cl)nc2-2)c-2[s]1)=O Chemical compound CC(Nc1nc(CCc2c(-c3c[o]cc3)[n](-c(cccc3)c3Cl)nc2-2)c-2[s]1)=O PBTKWUDQWQBJCK-UHFFFAOYSA-N 0.000 description 1
- XRTGWDJWGKKCDS-UHFFFAOYSA-N CC(Nc1nc(CCc2c-3[n](-c(c(Cl)c4)ccc4C(NC4CCN(C)CC4)=O)nc2-c2ccc[o]2)c-3[s]1)=O Chemical compound CC(Nc1nc(CCc2c-3[n](-c(c(Cl)c4)ccc4C(NC4CCN(C)CC4)=O)nc2-c2ccc[o]2)c-3[s]1)=O XRTGWDJWGKKCDS-UHFFFAOYSA-N 0.000 description 1
- WGZSGIHJVGWJGR-UHFFFAOYSA-N CC(Nc1nc(CCc2c-3[n](-c(cccc4)c4Cl)nc2N)c-3[s]1)=O Chemical compound CC(Nc1nc(CCc2c-3[n](-c(cccc4)c4Cl)nc2N)c-3[s]1)=O WGZSGIHJVGWJGR-UHFFFAOYSA-N 0.000 description 1
- AYTRCHIHIHKJQH-UHFFFAOYSA-N CC(Nc1nc(CCc2c-3[n](-c4ccccc4)nc2C(N(C)CCO)=O)c-3[s]1)=O Chemical compound CC(Nc1nc(CCc2c-3[n](-c4ccccc4)nc2C(N(C)CCO)=O)c-3[s]1)=O AYTRCHIHIHKJQH-UHFFFAOYSA-N 0.000 description 1
- CYHOMWAPJJPNMW-UHFFFAOYSA-N CN(C(CC1)C2)C1CC2O Chemical compound CN(C(CC1)C2)C1CC2O CYHOMWAPJJPNMW-UHFFFAOYSA-N 0.000 description 1
- GNGZZWTXFNFCMU-ZKCHVHJHSA-N CN(C)[C@H]1CC[C@H](N)CC1 Chemical compound CN(C)[C@H]1CC[C@H](N)CC1 GNGZZWTXFNFCMU-ZKCHVHJHSA-N 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N CN(CC1)CCN1N Chemical compound CN(CC1)CCN1N RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- CHPBRPQSTLXZKR-SOAUALDESA-N CS(=O)(=O)N1CCN(CC1)[C@H]1CC[C@@H](CC1)N(Cc1ccccc1)Cc1ccccc1 Chemical compound CS(=O)(=O)N1CCN(CC1)[C@H]1CC[C@@H](CC1)N(Cc1ccccc1)Cc1ccccc1 CHPBRPQSTLXZKR-SOAUALDESA-N 0.000 description 1
- LFYXYMNKXJPNGX-UHFFFAOYSA-N C[Mg]C(C)C Chemical compound C[Mg]C(C)C LFYXYMNKXJPNGX-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- BLHTXORQJNCSII-UHFFFAOYSA-N Cc1c[n](C)cn1 Chemical compound Cc1c[n](C)cn1 BLHTXORQJNCSII-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CNNDTJFOLKGSSJ-PQDNYVNLSA-N Cl.Cl.C1C(C)OC(C)CN1[C@@H]1CC[C@@H](N)CC1 Chemical compound Cl.Cl.C1C(C)OC(C)CN1[C@@H]1CC[C@@H](N)CC1 CNNDTJFOLKGSSJ-PQDNYVNLSA-N 0.000 description 1
- GSBVPGJFDHRFHF-WUSPCOQVSA-N ClC=1C=C(C=CC1F)NC1=NC=NC2=CC(=C(C=C12)OCCN1CCC(CC1)N1CC(OCC1)=O)OC.O1[C@@H](CCC1)COC1=NC2=CC=CC=C2C=N1 Chemical compound ClC=1C=C(C=CC1F)NC1=NC=NC2=CC(=C(C=C12)OCCN1CCC(CC1)N1CC(OCC1)=O)OC.O1[C@@H](CCC1)COC1=NC2=CC=CC=C2C=N1 GSBVPGJFDHRFHF-WUSPCOQVSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- LOFDXZJSDVCYAS-UHFFFAOYSA-N Ethyl 3-furoate Chemical compound CCOC(=O)C=1C=COC=1 LOFDXZJSDVCYAS-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- HDJLSECJEQSPKW-UHFFFAOYSA-N Methyl 2-Furancarboxylate Chemical compound COC(=O)C1=CC=CO1 HDJLSECJEQSPKW-UHFFFAOYSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- 101710202709 Middle T antigen Proteins 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- RBRJKARSVJGREO-UHFFFAOYSA-N N-(5-formyl-6-oxo-3a,4,5,6a-tetrahydrocyclopenta[d][1,3]thiazol-2-yl)acetamide Chemical compound C(=O)C1C(C2C(N=C(S2)NC(C)=O)C1)=O RBRJKARSVJGREO-UHFFFAOYSA-N 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- ULXXDDBFHOBEHA-INIZCTEOSA-N N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)C=CCN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-INIZCTEOSA-N 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- IPCRBOOJBPETMF-UHFFFAOYSA-N N-acetylthiourea Chemical compound CC(=O)NC(N)=S IPCRBOOJBPETMF-UHFFFAOYSA-N 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N NNC(c1ccccc1)=O Chemical compound NNC(c1ccccc1)=O WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N NOCc1ccccc1 Chemical compound NOCc1ccccc1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- MXZANEWAFZMPKW-UHFFFAOYSA-N N[n]1cncc1 Chemical compound N[n]1cncc1 MXZANEWAFZMPKW-UHFFFAOYSA-N 0.000 description 1
- QRZMXADUXZADTF-UHFFFAOYSA-N Nc1c[nH]cn1 Chemical compound Nc1c[nH]cn1 QRZMXADUXZADTF-UHFFFAOYSA-N 0.000 description 1
- MUGLENOZWVKNRY-UHFFFAOYSA-N Nc1c[o]cc1 Chemical compound Nc1c[o]cc1 MUGLENOZWVKNRY-UHFFFAOYSA-N 0.000 description 1
- BPKSYMQSNOQBGA-UHFFFAOYSA-N Nc1cccc(N(CCN2)C2=O)c1 Chemical compound Nc1cccc(N(CCN2)C2=O)c1 BPKSYMQSNOQBGA-UHFFFAOYSA-N 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- KRFNBNDDFCKXMQ-UHFFFAOYSA-N O1NC(CC2=C1C=CC=C2)=O.O2NC=CC1=C2C=CC=C1 Chemical class O1NC(CC2=C1C=CC=C2)=O.O2NC=CC1=C2C=CC=C1 KRFNBNDDFCKXMQ-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101150063858 Pik3ca gene Proteins 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical class C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- ZXQIEANXCQRVSZ-UHFFFAOYSA-N [3-[4-[6-[[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]hexoxy]butyl]phenyl]methanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC(CCCCOCCCCCCNCC(O)C=2C=C(CO)C(O)=CC=2)=C1 ZXQIEANXCQRVSZ-UHFFFAOYSA-N 0.000 description 1
- HGQSWGUVSJUFJD-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxypiperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CCOCC3)C(OCCOC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 HGQSWGUVSJUFJD-UHFFFAOYSA-N 0.000 description 1
- XWWOHHCWNCPYHQ-UHFFFAOYSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-(2-methylmorpholin-4-yl)methanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3CC(C)OCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XWWOHHCWNCPYHQ-UHFFFAOYSA-N 0.000 description 1
- GDZDVSVAWGOPPB-CALCHBBNSA-N [4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]-[(2r,6s)-2,6-dimethylmorpholin-4-yl]methanone Chemical compound C=12C=C(OC3CCN(CC3)C(=O)N3C[C@@H](C)O[C@@H](C)C3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 GDZDVSVAWGOPPB-CALCHBBNSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005025 alkynylaryl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
- 229950009746 arofylline Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 229950006944 atizoram Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- YYXYBWIDIWTCGS-UHFFFAOYSA-N chembl363685 Chemical compound NC(=N)C1=CC=C(O)C=C1 YYXYBWIDIWTCGS-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960003686 chlorphenoxamine Drugs 0.000 description 1
- KKHPNPMTPORSQE-UHFFFAOYSA-N chlorphenoxamine Chemical compound C=1C=C(Cl)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KKHPNPMTPORSQE-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229950001653 cilomilast Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- SGDINNZGYDHHKM-UHFFFAOYSA-N dilithium;trimethylsilylazanide Chemical compound [Li+].[Li+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] SGDINNZGYDHHKM-UHFFFAOYSA-N 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- NSWSKIBSHWBGLB-UHFFFAOYSA-N ethyl 2-acetamido-7-oxo-5,6-dihydro-4h-1,3-benzothiazole-6-carboxylate Chemical compound O=C1C(C(=O)OCC)CCC2=C1SC(NC(C)=O)=N2 NSWSKIBSHWBGLB-UHFFFAOYSA-N 0.000 description 1
- INQHUOSZSYRVHB-UHFFFAOYSA-N ethyl 7-acetamido-4,5-dihydro-1h-pyrazolo[4,3-g][1,3]benzothiazole-3-carboxylate Chemical compound CCOC(=O)C1=NNC2=C1CCC1=C2SC(NC(C)=O)=N1 INQHUOSZSYRVHB-UHFFFAOYSA-N 0.000 description 1
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 description 1
- OIVSLWMZGJLGKG-UHFFFAOYSA-N ethylthiourea;hydrobromide Chemical compound Br.CCNC(S)=N OIVSLWMZGJLGKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- QAIOVDNCIZSSSF-RFAJLIJZSA-N etiprednol dicloacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@@H]2O QAIOVDNCIZSSSF-RFAJLIJZSA-N 0.000 description 1
- 229950006990 etiprednol dicloacetate Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical class C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- GRGKPEOJEBTNSO-UHFFFAOYSA-N hydrazinylmethyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCNN GRGKPEOJEBTNSO-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 229950002451 ibuterol Drugs 0.000 description 1
- VSAPGYMUGNGYBG-UHFFFAOYSA-N imidazol-1-yl-(1-methylimidazol-4-yl)methanone Chemical compound CN1C=NC(C(=O)N2C=NC=C2)=C1 VSAPGYMUGNGYBG-UHFFFAOYSA-N 0.000 description 1
- IOADAVKYGCHPDQ-UHFFFAOYSA-N imidazol-1-yl-[1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methanone Chemical compound C[Si](C)(C)CCOCN1C=NC(C(=O)N2C=NC=C2)=C1 IOADAVKYGCHPDQ-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- QTBFPMKWQKYFLR-UHFFFAOYSA-N isobutyl chloride Chemical compound CC(C)CCl QTBFPMKWQKYFLR-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950008462 lirimilast Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical class COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- WKVJBYKFGNVWLM-UHFFFAOYSA-N methyl 4-amino-3-chlorobenzoate Chemical compound COC(=O)C1=CC=C(N)C(Cl)=C1 WKVJBYKFGNVWLM-UHFFFAOYSA-N 0.000 description 1
- FXXQDYPNDZFBMV-UHFFFAOYSA-N methyl 5-cyano-5-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-oxocyclohexane-1-carboxylate Chemical compound C1CC(=O)C(C(=O)OC)CC1(C#N)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 FXXQDYPNDZFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- QJQYPZZUKLQGGT-UHFFFAOYSA-N methyl hypobromite Chemical compound COBr QJQYPZZUKLQGGT-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
- WCUWHUUPGXCMMQ-UHFFFAOYSA-N morpholine-4-carboximidamide Chemical compound NC(=N)N1CCOCC1 WCUWHUUPGXCMMQ-UHFFFAOYSA-N 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- XUNVUVGDDZXFQN-UHFFFAOYSA-N n-(1-benzoyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C=NN1C(=O)C1=CC=CC=C1 XUNVUVGDDZXFQN-UHFFFAOYSA-N 0.000 description 1
- DMPPJEBFJRQJPW-UHFFFAOYSA-N n-(1-cyclohex-2-en-1-yl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C=NN1C1CCCC=C1 DMPPJEBFJRQJPW-UHFFFAOYSA-N 0.000 description 1
- BNAKCUPVFZSUFP-UHFFFAOYSA-N n-(1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C=NN1C1=CC=CC=C1 BNAKCUPVFZSUFP-UHFFFAOYSA-N 0.000 description 1
- OAPPCRWPMRBLAO-UHFFFAOYSA-N n-(1-phenyl-4h-pyrazolo[2,3]cyclopenta[2,4-b][1,3]thiazol-6-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CC=2C=NN1C1=CC=CC=C1 OAPPCRWPMRBLAO-UHFFFAOYSA-N 0.000 description 1
- HIWJHTYCHUAQET-UHFFFAOYSA-N n-(2-acetamido-4,5-dihydrobenzo[g][1,3]benzothiazol-8-yl)-2-methylpropanamide Chemical compound C12=CC(NC(=O)C(C)C)=CC=C2CCC2=C1SC(NC(C)=O)=N2 HIWJHTYCHUAQET-UHFFFAOYSA-N 0.000 description 1
- MVJPUUDNLUPGME-UHFFFAOYSA-N n-(2-benzoyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound N1=C2C=3SC(NC(=O)C)=NC=3CCC2=CN1C(=O)C1=CC=CC=C1 MVJPUUDNLUPGME-UHFFFAOYSA-N 0.000 description 1
- BKLKIUGRBIBDMZ-UHFFFAOYSA-N n-(2-cyclohex-2-en-1-yl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound N1=C2C=3SC(NC(=O)C)=NC=3CCC2=CN1C1CCCC=C1 BKLKIUGRBIBDMZ-UHFFFAOYSA-N 0.000 description 1
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 1
- ISYNGYKOIRHUMQ-UHFFFAOYSA-N n-(3-amino-1-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl)acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(N)=NN1C1=CC=CC=C1 ISYNGYKOIRHUMQ-UHFFFAOYSA-N 0.000 description 1
- HPSUJEVGXIZVDC-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-ethoxy-6-(oxan-4-yloxy)quinazolin-4-amine Chemical compound C=12C=C(OC3CCOCC3)C(OCC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 HPSUJEVGXIZVDC-UHFFFAOYSA-N 0.000 description 1
- FOFFXFJAROVKLF-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(1-methylpiperidin-4-yl)oxyquinazolin-4-amine;n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(oxan-3-yloxy)quinazolin-4-amine Chemical compound C=12C=C(OC3COCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1.C=12C=C(OC3CCN(C)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 FOFFXFJAROVKLF-UHFFFAOYSA-N 0.000 description 1
- XFENZNCAYAJOQE-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-7-methoxy-6-(1-methylsulfonylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C=C(OC3CCN(CC3)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XFENZNCAYAJOQE-UHFFFAOYSA-N 0.000 description 1
- AXUKMHZUBSEERL-UHFFFAOYSA-N n-(3-ethynylphenyl)-7-methoxy-6-(1-methylsulfonylpiperidin-4-yl)oxyquinazolin-4-amine Chemical compound C=12C=C(OC3CCN(CC3)S(C)(=O)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AXUKMHZUBSEERL-UHFFFAOYSA-N 0.000 description 1
- PFXSVTNJRIMDNZ-UHFFFAOYSA-N n-(7-morpholin-4-yl-4h-[1,3]thiazolo[4,5]cyclopenta[1,2-d]pyrimidin-2-yl)acetamide Chemical compound N1=C2C=3SC(NC(=O)C)=NC=3CC2=CN=C1N1CCOCC1 PFXSVTNJRIMDNZ-UHFFFAOYSA-N 0.000 description 1
- VXXUKWLHWFFUNS-UHFFFAOYSA-N n-(7-oxo-5,6-dihydro-4h-1,3-benzothiazol-2-yl)acetamide Chemical compound C1CCC(=O)C2=C1N=C(NC(=O)C)S2 VXXUKWLHWFFUNS-UHFFFAOYSA-N 0.000 description 1
- FOSHYZQGGBGKNS-UHFFFAOYSA-N n-(8-phenyl-4,5-dihydro-[1,3]thiazolo[4,5-h]quinazolin-2-yl)acetamide Chemical compound N1=C2C=3SC(NC(=O)C)=NC=3CCC2=CN=C1C1=CC=CC=C1 FOSHYZQGGBGKNS-UHFFFAOYSA-N 0.000 description 1
- SQARTHSIUZWAJG-PEHGTWAWSA-N n-[(6s)-7-oxo-6-(oxolane-2-carbonyl)-5,6-dihydro-4h-1,3-benzothiazol-2-yl]acetamide Chemical compound O=C([C@@H]1CCC=2N=C(SC=2C1=O)NC(=O)C)C1CCCO1 SQARTHSIUZWAJG-PEHGTWAWSA-N 0.000 description 1
- ASHDNTDMVNCNMK-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-3-(1-methylimidazol-4-yl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C=2N=CN(C)C=2)=NN1C1=CC=CC=C1Cl ASHDNTDMVNCNMK-UHFFFAOYSA-N 0.000 description 1
- OXIFKZYGXUEOKM-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-3-(furan-2-yl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C=2OC=CC=2)=NN1C1=CC=CC=C1Cl OXIFKZYGXUEOKM-UHFFFAOYSA-N 0.000 description 1
- KINXQBMFZJSYMQ-MRXNPFEDSA-N n-[1-(2-chlorophenyl)-3-[(2r)-oxolan-2-yl]-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C([C@@H]2OCCC2)=NN1C1=CC=CC=C1Cl KINXQBMFZJSYMQ-MRXNPFEDSA-N 0.000 description 1
- KINXQBMFZJSYMQ-INIZCTEOSA-N n-[1-(2-chlorophenyl)-3-[(2s)-oxolan-2-yl]-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C([C@H]2OCCC2)=NN1C1=CC=CC=C1Cl KINXQBMFZJSYMQ-INIZCTEOSA-N 0.000 description 1
- HKKKEXNSRHSTIP-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-3-methyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C)=NN1C1=CC=CC=C1Cl HKKKEXNSRHSTIP-UHFFFAOYSA-N 0.000 description 1
- GBMMFIGVSBUNIQ-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-3-phenyl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C=2C=CC=CC=2)=NN1C1=CC=CC=C1Cl GBMMFIGVSBUNIQ-UHFFFAOYSA-N 0.000 description 1
- YWHCGBUAFWGCKT-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-3-propan-2-yl-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1CC=2N=C(NC(C)=O)SC=2C2=C1C(C(C)C)=NN2C1=CC=CC=C1Cl YWHCGBUAFWGCKT-UHFFFAOYSA-N 0.000 description 1
- LIVYHJBCOLUXEK-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-4h-pyrazolo[2,3]cyclopenta[2,4-b][1,3]thiazol-6-yl]-4-(dimethylamino)butanamide Chemical compound C1=2C=3SC(NC(=O)CCCN(C)C)=NC=3CC=2C=NN1C1=CC=CC=C1Cl LIVYHJBCOLUXEK-UHFFFAOYSA-N 0.000 description 1
- JGWKCFQWJWUXTD-UHFFFAOYSA-N n-[1-(2-methylphenyl)-4h-pyrazolo[2,3]cyclopenta[2,4-b][1,3]thiazol-6-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CC=2C=NN1C1=CC=CC=C1C JGWKCFQWJWUXTD-UHFFFAOYSA-N 0.000 description 1
- YYFBYOJANXBYFY-UHFFFAOYSA-N n-[1-[4-(morpholine-4-carbonyl)phenyl]-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C=NN1C(C=C1)=CC=C1C(=O)N1CCOCC1 YYFBYOJANXBYFY-UHFFFAOYSA-N 0.000 description 1
- FKJQCIVCKMPEER-UHFFFAOYSA-N n-[1-phenyl-3-(trifluoromethyl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2C=3SC(NC(=O)C)=NC=3CCC=2C(C(F)(F)F)=NN1C1=CC=CC=C1 FKJQCIVCKMPEER-UHFFFAOYSA-N 0.000 description 1
- SXNMAVYVNAJYFP-UHFFFAOYSA-N n-[2-(2-chlorophenyl)-3-(1-methylimidazol-4-yl)-4,5-dihydropyrazolo[4,3-g][1,3]benzothiazol-7-yl]acetamide Chemical compound C1=2SC(NC(=O)C)=NC=2CCC=2C1=NN(C=1C(=CC=CC=1)Cl)C=2C1=CN(C)C=N1 SXNMAVYVNAJYFP-UHFFFAOYSA-N 0.000 description 1
- YBTWSPCOMHYEKP-UHFFFAOYSA-N n-[2-[4-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]ethyl]acetamide Chemical compound C=12C=C(OC3CCN(CCNC(C)=O)CC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 YBTWSPCOMHYEKP-UHFFFAOYSA-N 0.000 description 1
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 description 1
- RZWHMWFZGYRQSS-LJQANCHMSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[(2r)-2-(methoxymethyl)-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@@H](COC)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 RZWHMWFZGYRQSS-LJQANCHMSA-N 0.000 description 1
- KMAPIHHPUBUULD-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[2-methoxyethyl(methyl)amino]but-2-enamide Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(C)CCOC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 KMAPIHHPUBUULD-UHFFFAOYSA-N 0.000 description 1
- ULXXDDBFHOBEHA-MRXNPFEDSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N1=CN=C2C=C(O[C@H]3COCC3)C(NC(=O)C=CCN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-MRXNPFEDSA-N 0.000 description 1
- ATAWJUSPCXEYBT-UHFFFAOYSA-N n-[4-(dibenzylamino)cyclohexylidene]hydroxylamine Chemical compound C1CC(=NO)CCC1N(CC=1C=CC=CC=1)CC1=CC=CC=C1 ATAWJUSPCXEYBT-UHFFFAOYSA-N 0.000 description 1
- BJWZYXJMLUECMC-UHFFFAOYSA-N n-[6-(1-methylimidazole-4-carbonyl)-7-oxo-5,6-dihydro-4h-1,3-benzothiazol-2-yl]acetamide Chemical compound O=C1C=2SC(NC(=O)C)=NC=2CCC1C(=O)C1=CN(C)C=N1 BJWZYXJMLUECMC-UHFFFAOYSA-N 0.000 description 1
- QEJJLVMZHMHQMG-UHFFFAOYSA-N n-[6-(2-methoxyacetyl)-7-oxo-5,6-dihydro-4h-1,3-benzothiazol-2-yl]acetamide Chemical compound O=C1C(C(=O)COC)CCC2=C1SC(NC(C)=O)=N2 QEJJLVMZHMHQMG-UHFFFAOYSA-N 0.000 description 1
- BHPFBHBBRWHSAS-UHFFFAOYSA-N n-[6-(dimethylaminomethylidene)-7-oxo-4,5-dihydro-1,3-benzothiazol-2-yl]acetamide Chemical compound O=C1C(=CN(C)C)CCC2=C1SC(NC(C)=O)=N2 BHPFBHBBRWHSAS-UHFFFAOYSA-N 0.000 description 1
- ADOYXBQVLRRQGX-OAQYLSRUSA-N n-[7-cyclopentyloxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=CC=2NC(=O)C=CCN3CCOCC3)=NC=NC1=CC=2OC1CCCC1 ADOYXBQVLRRQGX-OAQYLSRUSA-N 0.000 description 1
- GWJKSCWOHYCDOC-UHFFFAOYSA-N n-[7-oxo-6-(3-trimethylsilylprop-2-ynoyl)-5,6-dihydro-4h-1,3-benzothiazol-2-yl]acetamide Chemical compound C1CC(C(=O)C#C[Si](C)(C)C)C(=O)C2=C1N=C(NC(=O)C)S2 GWJKSCWOHYCDOC-UHFFFAOYSA-N 0.000 description 1
- KVMHXALXHDZGEF-UHFFFAOYSA-N n-[8-(dimethylamino)-4,5-dihydro-[1,3]thiazolo[4,5-h]quinazolin-2-yl]acetamide Chemical compound C12=NC(N(C)C)=NC=C2CCC2=C1SC(NC(C)=O)=N2 KVMHXALXHDZGEF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- GRSBAMVBFWRBBH-UHFFFAOYSA-N o-ethyl chloromethanethioate Chemical compound CCOC(Cl)=S GRSBAMVBFWRBBH-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- COUYJEVMBVSIHV-UHFFFAOYSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NCC(O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-UHFFFAOYSA-N 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- DXGNOXBKPTWCHE-UHFFFAOYSA-N pentalen-2-amine Chemical compound C1=C(C=C2C=CC=C12)N DXGNOXBKPTWCHE-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- GEOWCLRLLWTHDN-UHFFFAOYSA-N phenyl formate Chemical compound O=COC1=CC=CC=C1 GEOWCLRLLWTHDN-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000009024 positive feedback mechanism Effects 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004314 regulation of intracellular transport Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 229950000366 roxindole Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229950001879 salmefamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229950010289 soterenol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950008418 talipexole Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- DHHKPEUQJIEKOA-UHFFFAOYSA-N tert-butyl 2-[6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetate Chemical compound C1C=CC2C(CC(=O)OC(C)(C)C)(C[N+]([O-])=O)CC21 DHHKPEUQJIEKOA-UHFFFAOYSA-N 0.000 description 1
- KHPQHXGYYXYTDN-UHFFFAOYSA-N tert-butyl n-(piperidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCCNC1 KHPQHXGYYXYTDN-UHFFFAOYSA-N 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- LHZRSNVQLBOUNH-UHFFFAOYSA-N tert-butyl n-[[1-(2,2,2-trifluoroacetyl)piperidin-4-yl]amino]carbamate Chemical compound CC(C)(C)OC(=O)NNC1CCN(C(=O)C(F)(F)F)CC1 LHZRSNVQLBOUNH-UHFFFAOYSA-N 0.000 description 1
- YHGONTNNHYEBEA-UHFFFAOYSA-N tert-butyl n-[[1-(2,2,2-trifluoroacetyl)piperidin-4-ylidene]amino]carbamate Chemical compound CC(C)(C)OC(=O)NN=C1CCN(C(=O)C(F)(F)F)CC1 YHGONTNNHYEBEA-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- DSPYCWLYGXGJNJ-UHFFFAOYSA-N tert-butyl n-prop-2-ynylcarbamate Chemical compound CC(C)(C)OC(=O)NCC#C DSPYCWLYGXGJNJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical class [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
- XJBCFFLVLOPYBV-UHFFFAOYSA-N zinterol Chemical compound C=1C=C(O)C(NS(C)(=O)=O)=CC=1C(O)CNC(C)(C)CC1=CC=CC=C1 XJBCFFLVLOPYBV-UHFFFAOYSA-N 0.000 description 1
- 229950004209 zinterol Drugs 0.000 description 1
- XJSMBWUHHJFJFV-VTIMJTGVSA-N α-dihydroergocryptine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3[C@H]1C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XJSMBWUHHJFJFV-VTIMJTGVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/84—Naphthothiazoles
Definitions
- Phosphatidylinositol 3-kinases are a subfamily of lipid kinases that catalyze the transfer of a phosphate moiety to the 3'-position of the inositol ring of phosphoinositides (Vanhaesebroeck and Waterfield, Exp. Cell Res. 1999 Nov 25; 253 (1): 239-54).
- PI3 kinases Due to their in vivo specificity for certain phosphoinositide substrates, the PI3 kinases can be divided into different classes.
- the members of the receptor-regulated class I are heterodimeric enzymes composed of a 1 10-120 kDa catalytic (p110) and a 50-101 kDa non-catalytic subunit (p50, p55, p85, p101).
- the most highly conserved region in all PI3 kinases is the C-terminal kinase domain. It has structural features that are also found in most known protein kinases. These include e.g. also highly conserved amino acids, which are responsible for the
- PI3 kinases constitutively associate with a 50-85 kDa adapter subunit, of which p85 is the prototype.
- the interaction occurs via the so-called p85 binding domain, which can be found on the catalytic subunits of the PI3 kinase ⁇ , ß and ⁇ .
- the three forms are grouped into Class IA because of this structural feature.
- the catalytic subunit of PI3 kinase ⁇ , p1 10 ⁇ instead associates with a 101 kDa regulatory protein called p101. It is - so far the only member - the class IB of the PI3 kinases.
- PI3K ⁇ is primarily activated by G ⁇ subunits released from heterotrimeric G proteins upon activation of heptahelical receptors. This different coupling to cell surface receptors in combination with a more or less restrictive expression inevitably results in very different tasks and functions of the 4 class I PI3 kinases in the intact organism (Wymann et al., Trends Pharmacol Sei. 2003 Jul; 7): 366-76).
- PI3-kinase activity was associated with the transforming activity of viral oncogenes, e.g. the middle T antigen of polyomavirus, Src
- Tyrosine kinases or activated growth factors (Workman, Biochem Soc Trans. 2004 Apr; 32 (Pt 2): 393-6).
- tumors e.g. Breast cancer, ovarian or even pancreatic carcinoma
- Akt / PKB an overactivity of Akt / PKB, which is activated directly by the lipid products of class I PI3 kinases and thus passes the signals into the cell.
- the PIK3CA gene coding for p110 ⁇ has a high frequency of mutations in several tumor types, such as colon, mammary or lung carcinomas, some of which have been characterized as activating mutations (Samuels et al , Science, 2004 Apr 23; 304 (5670): 554).
- mice The youngest member of the class IA PI3 kinases, the PI3K ⁇ , is more restrictively expressed than the PI3K ⁇ and ⁇ .
- PI3K ⁇ The youngest member of the class IA PI3 kinases, the PI3K ⁇ , is more restrictively expressed than the PI3K ⁇ and ⁇ .
- knock-in mice in which the catalytic subunit of PI3K ⁇ , p110 ⁇ , was replaced by an inactive mutant, it could be shown that this PI3K isoenzyme a specific role in the signal transmission of B and T lymphocytes after antigen-receptor stimulation (Okkenhaug et al., Science 2002 Aug; 297 (5583): 1031-4) .
- the PI3K ⁇ is activated almost exclusively by G-coupling heptahelical receptors. , Science formation can be observed when these were stimulated with IL-8, fMLP, LTB4 or C5a (Hirsch et al 2000 - so could in neutrophils in mice which express no PI3K ⁇ , no PI3, 4, 5-P. 3. Feb 11; 287 (5455): 1049-53). This demonstrates that, at least in this cell type, PI3K ⁇ is the only PI3 kinase isoform that couples to these heptahelical receptors.
- PI3K ⁇ plays a central role in the activation of various inflammatory cells, and therefore isoform-specific inhibitors represent an attractive option for anti-inflammatory therapy with comparatively low side effects (Ward and Finan, Curr Opin Pharmacol Aug; 3 (4): 426-34)
- PI3K ⁇ also appears to play a role in the cardiovascular system despite its low expression in cardiomyocytes.
- mice showed an increase in myocardial contractility, which can probably be explained by an overproduction of cAMP (Crackower et al., Cell 2002 Sep 20; 10 (6): 737-49).
- cAMP cAMP-activated kinase
- PI3K ⁇ is also involved in the development of cardiac hypertrophy.
- p110 ⁇ -deficient mice in a isoproterenol-induced heart failure model showed a markedly reduced hypertrophy and fibrosis in comparison with the wild-type animals (Oudit et al., Circulation 2003 Oct 28; 108 (17): 2147-52).
- the object of the present invention was to provide novel compounds which, because of their pharmaceutical activity, can be used as a PI3-kinase modulator for use in the therapeutic field for the treatment of inflammatory or allergic diseases.
- inflammatory and allergic respiratory diseases inflammatory diseases of the gastrointestinal tract, rheumatoid arthritis, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic disease states in which autoimmune reactions are involved or called kidney inflammation.
- PI3-kinase inhibitors for the treatment of inflammatory diseases are known in the literature.
- WO 03/072557 discloses 5-phenylthiazole derivatives
- WO 04/029055 shows fused azolpyrimidines
- WO 04/007491 azolidinone-vinyl-linked benzene derivatives
- the two documents WO 04/052373 and WO 04/056820 disclose benzoxazine benzoxazine-3-one derivatives.
- Y is carbon, nitrogen, sulfur; preferably carbon, nitrogen; Z is carbon, nitrogen, sulfur; preferably carbon, nitrogen; j 1, 2 or 3; k is 0 or 1;
- R a is H, COR 8 , NR 9 R 10 , NO 2 , OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 -alkyl-NH 2 , or a radical selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 haloalkyl, aryl, C 7-11 aralkyl, spiro, Het, heteroaryl, and CH 2 -O-aryl which may be optionally substituted;
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 , CONR 12 or C 1-6 alkyl optionally substituted with one or more COOH, N (C 1-6 alkyl) 2 or Het optionally substituted with one or more C 1-6 alkyl ; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, d-beta-alkyl, CO-C 1-6 -alkyl or C 2-6 -alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (d -4 alkyl) 2 ;
- R 4 , R 5 H C 1-6 -alkyl, d- ⁇ -haloalkyl, C 1-6 -alkylene-OH, C 2-6 -alkenyl, C 7-11 -aralkyl, C 2-4 -alkenyl- Aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-H ⁇ -taryl, C 2-4 -alkenyl-hetaryl, C 2-4 -alkynyl-hetaryl, C 2-6 -alkynyl, optionally substituted with Si ( C 1-4 alkyl) 3 , or R 4 is a radical selected from the group consisting of aryl, het, hetaryl and optionally substituted by C 1-4 alkyl;
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur; 1 c NHR 6 or a radical selected from the group consisting of
- B bond C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, het, aryl, hetaryl optionally substituted with one or more R 6 1 ;
- R 6 1 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 7 is H, C 1-6 alkyl, (CH 2 ) 2 _ 4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl;
- R a is a radical selected from the group consisting of aryl, C 7-11 -aralkyl and
- Heteroaryl which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 1-6 haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 OH C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, NR 1 1 1 R 1 1 2
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- X is bond or C 1-4 alkylene
- X ' is C 1-4 -alkylene, C 2-4 -alkenylene or C 1-4 -alkynylene
- R 3a is a radical, identical or different, selected from the group consisting of R 3 1 , R 32 and R 33 ;
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 3 1 1 C 1-6 -alkyl, C 2-6 -alkenyl, OH, C 1-4 -alkylene-OH, C 1-4 -alkylene-NR 3 1 1 1 R 3 1 1 2 ', COR 3 1 1 1 , COOR 3 1 1 1 ,
- R 3 1 1 1 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and d-iralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN;
- R 3 1 1 2 H, C 1-4 alkyl
- R 32 is a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or more R 32 1 R 321 is C 1-6 alkyl, C 3-6 cycloalkyl, OH, NR 3211 R 3212 , NHCOR 3213 or Het optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , CH 2 -C 3-6 cycloalkyl and aryl;
- R 3211 is H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 aryl, C 7-11 aralkyl or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-8 alkyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more Radicals selected from the group halogen, C 1-6 -alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 is H or C 1-6 alkyl, aryl, C 7-11 aralkyl
- R 3222 is H or C 1-6 alkyl
- Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-
- N is (C 1-6 alkyl) 2 or Het, wherein Het may optionally be substituted with a C 1-6 alkyl radical;
- H or a radical selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl and aryl which may be optionally substituted with one or more radicals R 331 .
- R 331 C 3-6 cycloalkyl, C 3 _ 6 cycloalkenyl, OR 3311, NR 3311 R 3312, CONR 3311 R 3312, COOR 3311, NR 3311 3312 COR, SOR 3311, SO 2 R 33 1 1 , C (NR 33 1 1 R 33 1 2 ) NR 33 1 3 , NR 33 1 1 CONR 33 1 2 R 33 1 3 , OH, CN, halogen or Het, optionally substituted with one or more Radicals selected from the group consisting of C 1-4 alkyl, SO 2 H, SO 2 C 1-4 alkyl, SO 2 C 7-11 aralkyl, CH 2 -C 3-6 cycloalkyl and aryl;
- R 33 1 1 , R 33 1 2 and R 33 1 3 is a radical selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 7-11 -aralkyl, C 2-4 -alkenyl-aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-hetaryl, C 2-4 -alkenyl-hetaryl, C 2-4 -alkynyl-hetaryl,
- R 33 1 1 , R 3 3 1 2 and R 33 1 3 together form a ring consisting of carbon atoms and optionally one
- Heteroatom selected from the group consisting of oxygen, nitrogen and sulfur
- R a is H, Ci-8-alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 haloalkyl, COR 8, NR 9 R 10, NO 2, OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 alkyl-NH 2l spiro or a
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 , CONR 12 or C 1-6 alkyl optionally substituted with one or more COOH, N (C 1-6 alkyl) 2 or Het optionally substituted with one or more C 1-6 alkyl ; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 1 0 H, C 1-6 alkyl, CO-C 1-6 alkyl or C 2-6 alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is H, C 1-6 -alkyl
- R a is a radical selected from the group consisting of aryl, C 7-11 aralkyl and hetaryl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 1-6 haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -Aikoxy 1 halogen, OH, CN, COR 1 1 , OC 1-4 haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 OH C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, NR 1 1 1 R 1 1 2
- R 1 1 2 H, C 1-6 alkyl
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 31 , R 32 and R 33 ;
- R 31 is spiro or het, where Het may be optionally substituted with one or more R 311 ;
- R 311 is C 1-6 alkyl, C 2-6 alkenyl, OH, C 1-4 alkylene-OH, C 1-4 alkylene NR 3111 R 3112 , COR 3111 , COOR 3111 , CONR 3111 R 3112 , NR 3111 R 3112, Het, hetaryl, NHCOR 3111
- R 3111 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and C 7-11 aralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN;
- R 3112 is H, C 1-4 alkyl; a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or more R 321
- R 321 is C 1-6 alkyl, C 3-6 cycloalkyl, OH, NR 3211 R 3212 , NHCOR 3213 or
- Het optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , CH 2 -C 3-6 cycloalkyl and aryl;
- R 3211 H 1 C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl; R 3212 aryl, C 7-11 aralkyl; or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more Radicals selected from the group halogen, C 1-6 -alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 is H or C 1-6 alkyl, aryl, C 7-11 aralkyl R 3222 H or C 1-6 alkyl; or
- Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-N (C 1-6 -alkyl) 2 or Het, where Het may optionally be substituted by a radical C 1-6 -alkyl;
- R 33 is H or a radical selected from the group consisting of C 16 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl and aryl which may be optionally substituted by one or more radicals R 331 ;
- R 331 C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, OR 3311 , NR 3311 R 3312 ,
- CONR 3311 R 3312 COOR 3311 , NR 3311 COR 3312 , SOR 3311 , SO 2 R 3311 , C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH, CN, halogen or Het, optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 H, SO 2 C 1-4 alkyl, SO 2 C 7-11 aralkyl,
- R 3311 , R 3312 and R 3313 are a radical selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, Cy-n-aralkyl, C 2-4 -alkenyl- Aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-
- a ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R a is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3 _ 8 cycloalkenyl, C 1-6 haloalkyl, COR 8, NR 9 R 10, NO 2, OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 -alkyl-NH 2 , spiro or a radical selected from the group consisting of C 7-11 -aralkyl, CH 2 -O-aryl and Het which may optionally be substituted with one or more halo, C 1-6 alkyl, CO-C 1-4 haloalkyl, C 1-4 alkyl-NH 2 or CH 2 NHCOOR 12 ;
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 , CONR 12 or C 1-6 alkyl optionally substituted with one or more COOH, N (C 1-6 alkyl) 2 or Het optionally substituted with one or more C 1-6 alkyl ; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, C 1-6 -alkyl, CO-C 1-6 -alkyl or C 2-6 -alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is H, C 1-6 -alkyl
- R a is a radical selected from the group consisting of aryl, C 7- n -aralkyl and hetaryl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 1-6 haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 OH C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, NR 1 1 1 R 1 1 2
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 3 1 , R 32 and R 33 ;
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 3 1 1 C 1-6 -alkyl, C 2-6 -alkenyl, OH, C 1-4 -alkylene-OH, C 1-4 -alkylene-NR 3 1 1 1 R 3 1 1 2.
- COR 3 1 1 1 , COOR 3 1 1 1 , CONR 3 1 1 1 R 3 1 1 2 , NR 3 1 1 1 R 3 1 1 2 , Het, hetaryl, NHCOR 3 1 1 1 R 3111 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and C 7-11 aralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN;
- R 3112 is H, C 1-4 alkyl
- R 3 2 is a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or more R 3 21
- R 321 is C 1-6 alkyl, C 3-6 cycloalkyl, OH, -NR 3211 R 3212 , NHCOR 3213 or Het, optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , CH 2 -C 3-6 cycloalkyl and aryl;
- R 3211 is H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 aryl, C 7-11 aralkyl or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more Radicals selected from the group halogen, C 1-4 -alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 H or C 1-6 alkyl, aryl, C 7-1 ! aralkyl
- R 3222 is H or C 1-6 alkyl
- Aryl optionally substituted with one or two R 323 R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-N (C 1-6 -alkyl) 2 or Het, wherein Het may optionally be substituted by a radical C 1 6 -alkyl;
- R 33 is H or a radical selected from the group consisting of C 1-6 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl and aryl which may be optionally substituted with one or more several radicals R 33 1 ;
- R 3 3 1 C 5-6 -cycloalkyl, C 1-6 -cycloalkenyl, OR 33 1 1 , NR 3 3 1 1 R 3 3 1 2 , CONR 3 3 1 1 R 3 3 1 2 , COOR 33 1 1 , NR 3 3 1 1 COR 3 3 1 2 , SOR 33 1 1 ,
- R 33 1 1 , R 33 1 2 and R 33 1 3 is a radical selected from the group consisting of C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 7-11 -aralkyl, C 2-4 -alkenyl-aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-hetaryl, C 2-4 -alkenyl-hetaryl, C 2-4 -alkynyl-hetaryl,
- R 33 1 1 , R 3 3 1 2 and R 3 3 1 3 together form a five-, six- or seven-membered ring consisting of
- R 9 is H, COOR 12 or C 1-4 alkyl optionally substituted with one or more COOH, N (C 1-4 alkyl) 2 or Het optionally substituted with one or more C 1-4 alkyl; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, C 1-6 -alkyl, CO-C 1-4 -alkyl or C 2-6 -alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is C 1-6 alkyl
- R 4 is H, C 1-8 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkylene-OH, C 2-6 -alkenyl, C 7 _n -aralkyl, C 2-4 -alkenyl-aryl, C 2 -4 alkynyl-aryl, C 1-4 alkyl hetaryl, hetaryl-C 2-4 alkenyl, C 2-4 alkynyl-hetaryl, C 2-6 alkynyl, optionally substituted by Si (C 1. 4, -Alkyl) 3 , or R 4 is a radical selected from the group consisting of aryl, het, hetaryl and optionally substituted by C 1-4 alkyl;
- R 5 is H or C 1-6 alkyl
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, het, aryl, hetaryl optionally substituted with one or more R 61 ;
- R 61 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, NR 71 R 72 , OR 72 , SR 72 , hetaryl, Het optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 71 is H, C 1-4 alkyl, (CH 2 ) 2 _ 4 R 711 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7i 1 NR 7111 R 7112 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7112 H or C 1-6 alkyl
- R a is a radical selected from the group consisting of aryl, C 7-11 aralkyl and hetaryl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 1-6 haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 OH C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, NR 1 1 1 R 1 1 2
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 3 1 , R 32 and R 33 ;
- R 31 is spiro or het, where Het may be optionally substituted with one or more R 311 ;
- R 311 is C 1-6 -alkyl, C 2-6 -alkenyl, OH, C 1-4 -alkylene-OH, C 1-4 -alkylene-NR 3111 R 3112 , COR 3111 , COOR 3111 ,
- R 3111 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and C 7-11 aralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN;
- R 3112 is HC 1-4 alkyl
- R 32 is a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or more R 321
- R 321 is d- ⁇ -alkyl, C 3-6 -cycloalkyl, OH, -NR 3211 R 3212 , NHCOR 3213 or Het, optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 ,
- R 3211 is H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 aryl, C 7-11 aralkyl or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more remains selected from the group halogen, C 1-6 alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 H or C 1-6 alkyl, aryl, C 7 _ ir aralkyl 3222 R is H or C 1-6 alkyl; or
- Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-N (C 1-6 -alkyl) 2 or Het, where Het may optionally be substituted by a radical C 1-6 -alkyl;
- H or a radical selected from the group consisting of C 1-6 alkyl, C 2-4 alkenyl, C 2-4 alkynyl and aryl which may be optionally substituted with one or more R 331 radicals;
- R 331 Cs-e-cycloalkyl, C 5 - 6 cycloalkenyl, OR 3311, NR 3311 R 3312, CONR 3311 R 3312, 3311 COOR, COR NR 3311 3312, 3311 SOR, SO 2 R 3311, C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH, CN, halogen or Het, optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 H, SO 2 -C 1-4 -Alkyl, SO 2 C 7 _n-aralkyl, CH 2 -C 3-6 -cycloalkyl and aryl;
- R 3311 , R 3312 and R 3313 is a radical selected from the group consisting of C 1-4 alkyl, C 7-11 aralkyl, C 1-4 alkyl hetaryl, COC 1-4 alkyl-H ⁇ taryl; or
- R a is H, C 1-6 alkyl, C 2-6 alkenyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, Ci-8-haloalkyl, COR 8, NR 9 R 10, NO 2, OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 -alkyl-NH 2l, spiro or a radical selected from the group consisting of C 7-11 -aralkyl, CH 2 -O-aryl and Het of optionally substituted with one or more halo, C 1-6 alkyl, CO-C 1-4 haloalkyl, C 1-4 alkyl-NH 2 or CH 2 NHCOOR 12 ;
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 or C 1-4 alkyl optionally substituted with one or more COOH, N (C 1-4 alkyl) 2 or Het optionally substituted with one or more C 1-4 alkyl; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, C 1-6 -alkyl, CO-C 1-4 -alkyl or C 2-6 -alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is C 1-6 alkyl
- R b R 4 , OR 4 , -CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NR 5 COOR 4 , NR 5 CONR 4 R 5 or NR 5 SOR 4 ;
- R 4 is H, C 1-6 alkyl, d -6 haloalkyl, C 1-6 -alkylene-OH, C 2-6 alkenyl, C 7-11 aralkyl, C 1 4 alkyl hetaryl, C 2 -6- alkynyl optionally substituted with Si (C 1-4 -alkyl) 3 , or R 4 represents a radical selected from the group consisting of aryl, het, hetaryl and optionally substituted by C 1-4 -alkyl;
- R 5 is H or d- ⁇ -alkyl
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur; NHR 6 or a residue selected from the group consisting of
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 3-6 -cycloalkyl, het, aryl, hetaryl, optionally substituted by one or more radicals R 61 ;
- R 61 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 3-6 cycloalkyl, NR 71 R 72 , OR 72 , SR 72 , hetaryl, Het optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 71 is H, C 1-4 alkyl, (CH 2 ) 2 _ 4 R 711 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 711 NR 7111 R 7112 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R a is a radical selected from the group consisting of aryl and C 7-11 aralkyl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or hetaryl optionally substituted by one or more C 1-4 alkyl;
- R 1 is C 1-4 -alkyl, C 1-4 -haloalkyl, C 1-4 -alkylene-COOH, C 1-4 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SO 2 R 1 1 ;
- R 2 is C 1-4 alkyl, C 1-4 alkoxy or halo
- R 3 is a radical selected from the group consisting of
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 3 1 1 C 1-4 -alkyl, C 2-4 -alkenyl, OH, C 1-4 -alkylene-OH, CH 2 NEt 2 , COMe, COOH, CONH 2 , NH 2 , Het, hetaryl,
- R 321 C 1-4 alkyl, cyclopentyl, OH, NR 3211 R 3212 or
- R 3211 is H, methyl or benzyl
- R 3212 is H, methyl or benzyl
- R 322 C 2-4 alkenyl, C 2-4 alkynyl, COOR 3221 , CONR 3221 R 3222 ,
- NR 3221 R 3222 NHCOR 3221 , C 1-4 haloalkyl, CN, OH, SO 2 R 3221 , C 3-6 cycloalkyl or a radical selected from the group consisting of
- R 3221 is H or methyl;
- R 3222 is H or methyl; or
- Aryl optionally substituted with one or two R 323
- R 331 radicals H or a radical selected from the group consisting of C 1-6 alkyl and aryl which may be optionally substituted with one or more R 331 radicals;
- R 331 C 5-6 -cycloalkyl, C 5 - 6 cycloalkenyl, OR 3311, NR 3311 R 3312, CONR 3311 R 3312, 3311 COOR, COR NR 3311 3312, 3311 SOR, SO 2 R 3311, C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH, CN, halogen or Het, optionally substituted with one or more radicals selected from the group consisting of methyl, SO 2 H, SO 2 C 1-4 -alkyl, 1 SO 2 C 7-11 -aralkyl,
- R 33 1 1 , R 33 1 2 and R 33 1 3 is a radical selected from the group consisting of C 1-4 -alkyl, C 7-11 -aralkyl, C 1-4 -alkyl-hetaryl, COC 1-4 alkyl hetaryl;
- R 8 is C 1-4 alkyl, C 3-6 cycloalkyl, NH 2 , furanyl or phenyl optionally substituted with one or more chloro;
- R 9 is H, COOR 12 or piperidino, optionally substituted by one or more CH 3 , or a radical selected from the group consisting of C 1-4 -alkyl, which may optionally be substituted by one or more COOH, NMe 2 or 4- methylpiperazine;
- R 10 is H, C 1-4 alkyl, C 2-4 alkynyl or COCH 3 ;
- R 11 is C 1-4 -alkyl, optionally substituted by one or more NMe 2 ,
- R 12 is C 1-4 alkyl
- R b R 4 , CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NHCOOR 4 , NHCONR 4 R 5 or OH;
- R 4 is H, C 1-4 -alkyl, C 1-4 -alkylene-OH, C 2-4 -alkynyl, C 1-6 -haloalkyl, aryl, het, hetaryl,
- R c M NHR 6 or a radical selected from the group consisting of
- R 6 is H, C 1-4 alkyl, C 3-6 cycloalkyl, C 7-11 aralkyl, aryl optionally substituted with SO 2 CH 3 ;
- R 7 is H, NR 71 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted by C 1-4 alkyl or CONH 2 , or a radical selected from the group consisting of
- R 71 is H, C 1-4 alkyl, (CH 2 ) 2 R 711 or COOButyl;
- R 72 is H, C 1-4 alkyl;
- R 711 NR 7111 R 7112 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R a is phenyl or benzyl, each optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or
- R 1 is methyl, ethyl, propyl, butyl, CF 3, CH 2 COOH, methoxy, F, Cl, Br, OH, CN, COR 1 1, OCF 3, NO 2 or SO 2 R 1 1;
- R 2 is methyl, methoxy, F, Cl or Br
- R 3 is a radical selected from the group consisting of
- R 3 1 is a radical selected from the group consisting of
- R 32 is 1 H, methyl or benzyl; R 32 is H 2 , methyl or benzyl; or C 1-6 alkyl, straight or branched, which is optionally substituted with one or two R 322 ;
- R 322 C CH 2 , C ⁇ CH, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 ,
- NHCOR 3221 CF 3 , CN, OH, SO 2 R 3221 or a radical selected from the group consisting of
- R 3221 is H or methyl
- R 3222 is H or methyl
- R 323 is a radical selected from the group consisting of
- R 331 Cs-e-cycloalkyl, C 5 - 6 cycloalkenyl, OR 3311, NR 3311 R 3312, CONR 3311 R 3312, 3311 COOR, COR NR 3311 3312, 3311 SOR, SO 2 R 3311, C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH, CN, halogen or Het which is optionally substituted by one or more radicals selected from the group consisting of
- R 3311 , R 3312 and R 3313 are a radical selected from the group consisting of C 1-4 -alkyl, C 7-11 -aralkyl, C 1-4 -alkyl-hetaryl, COC 1-4 -alkyl-hetaryl; H, methyl, ethyl, propyl, butyl, 3-methyl-butyl, propenyl, cyclopropyl, cyclohexyl, CF 3 , COR 8 , NR 9 R 10 , NO 2 , OR 8 , SR 11 , SOR 11 , SO 2 R 11 or a residue selected from the group consisting of
- R 8 is methyl, propyl, cyclopropyl, NH 2 , furanyl or phenyl optionally substituted with one or more chloro;
- R 9 is H, COOR 12 or piperidino, optionally substituted with one or more CH 3 , or a radical selected from the group consisting of methyl, ethyl and propyl, which may be optionally substituted with one or more COOH, NMe 2 or 4-methylpiperazine ;
- R 11 is ethyl or propyl, optionally substituted by one or more NMe 2 ,
- R b R 4 , CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NHCOOR 4 , NHCONR 4 R 5 or OH;
- R 4 is H, methyl, ethyl, 2-hydroxyethyl, propyl, C 1 H 3 , CF 3 , phenyl,
- R 5 is H, methyl or ethyl
- B bond methylene, ethylene, propylene or butynylene
- R 6 is H, C 1-4 alkyl, aryl, optionally substituted with SO 2 CH 3 ;
- R 7 H NR 7 1 R 7 2 , OR 7 2 , SR 7 2 or a radical selected from the group consisting of
- R 7 is H, methyl, ethyl, (CH 2 ) 2 R 7 1 1 or COOButyl;
- R 72 is H, methyl or ethyl;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl;
- R a is a radical selected from the group consisting of aryl, C 7-11 aralkyl and hetaryl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 1-6 haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3a is a radical, identical or different, selected from the group consisting of R 3 1 , R 32 and R 33 ;
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 311 is C 1-6 alkyl, C 2-6 alkenyl, OH, C 1-4 alkylene-OH, C 1-4 alkylene NR 3111 R 3112 , COR 3111 , COOR 3111 , CONR 3111 R 3112 , NR 3111 R 3112, Het, hetaryl, NHCOR 3111
- R 3111 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and C 7-11 aralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN;
- R 3112 is H, C 1-4 alkyl
- R 321 is C 1-6 alkyl, C 3-6 cycloalkyl, OH, NR 3211 R 3212 , NHCOR 3213 or
- Het optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , CH 2 -C 3-6 cycloalkyl and aryl;
- R 3211 H 1 C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl; R 3212 aryl, C 7-11 aralkyl; or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more Radicals selected from the group halogen, C 1-6 -alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 is H or C 1-6 alkyl, aryl, C 7-11 aralkyl
- R 3222 is H or C 1-6 alkyl
- Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-
- N is (C 1-6 alkyl) 2 or Het, wherein Het may optionally be substituted with a C 1-6 alkyl radical;
- H or a radical selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl and aryl which may be optionally substituted with one or more radicals R 331 ;
- R 331 C 3-6 cycloalkyl, C 3-6 cycloalkenyl, OR 3311 , NR 3311 R 3312 , CONR 3311 R 3312 , COOR 3311 , NR 3311 COR 3312 , SOR 3311 , SO 2 R 3311 , C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH,
- CN halogen or Het optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , SO 2 C 1-4 alkyl, SO 2 C 7-11 aralkyl, CH 2 -C 3-6 -cycloalkyl and aryl;
- R 3311 , R 3312 and R 3313 is a radical selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 7-11 aralkyl, C 2-4 alkenyl -Aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-hetaryl, C 2-4 -alkenyl-hetaryl, C 2-4 -alkynyl-hetaryl, COC 1-4 -alkyl-hetaryl, COC 2 -4 alkenyl-hetaryl,
- R 3311 , R 3312 and R 3313 together form a ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen,
- R 4 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 -alkylene-OH, C 2-6 alkenyl, C 7 _ ir aralkyl, C 2-4 alkenyl Aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-hetaryl, C 2-4 -alkenyl-hetaryl, C 2-4 -alkynyl-hetaryl, C 2-6 -alkynyl, optionally substituted by Si ( C 1-4 alkyl) 3 , or R 4 is a radical selected from the group consisting of aryl, het, hetaryl and optionally substituted by C 1-4 alkyl;
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- B bond C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl;
- R 6 is H or a group selected from the group C 1 -C 4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, het, aryl, hetaryl optionally substituted with one or more R 6 1 ;
- R 6 1 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted C 1 4 alkyl or CONH 2;
- R 7 is H, C 1-6 -alkyl, (CH 2 ) 2 . 4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl;
- R a is a radical selected from the group consisting of aryl, dn-aralkyl and hetaryl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3 _ 6 cycloalkenyl, C 1-6 -haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -Aikoxy 1 halogen, OH, CN, COR 1 1 , OC 1-4 haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 OH C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, NR 1 1 1 R 1 1 2
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 31 , R 32 and R 33 ;
- R 31 is spiro or het, where Het may be optionally substituted with one or more R 311 ;
- R 311 is C 1-6 alkyl, C 2-6 alkenyl, OH, C 1-4 alkylene-OH, C 1-4 alkylene NR 3111 R 3112 , COR 3111 , COOR 3111 , CONR 3111 R 3112 , NR 3111 R 3112, Het, hetaryl, NHCOR 3111
- R 3111 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and C 7-11 aralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN;
- R 3112 is H, C 1-4 alkyl; a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or more R 321
- R 321 C 1-6 alkyl, C 3-6 cycloalkyl, OH , - NR 3211 R 3212 , NHCOR 3213 or
- Het optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , CH 2 -C 3-6 cycloalkyl and aryl;
- R 3211 H 1 C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl; R 3212 aryl, C 7-11 aralkyl; or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more Radicals selected from the group halogen, C 1-6 -alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 is H or C 1-6 alkyl, aryl, C 7-11 aralkyl R 3222 H or C 1-6 alkyl; or
- Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-N (C 1-6 -alkyl) 2 or Het, where Het may optionally be substituted by a radical C 1-6 -alkyl;
- R 33 is H or a radical selected from the group consisting of C 1-6 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 haloalkyl and aryl which may be optionally substituted with one or more several residues R 331 ;
- R 331 C 5 - 6 cycloalkyl, C 5 - 6 cycloalkenyl, OR 3311, NR 3311 R 3312,
- CONR 3311 R 3312 COOR 3311 , NR 3311 COR 3312 , SOR 3311 , SO 2 R 3311 , C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH, CN, halogen or Het, optionally substituted with one or more radicals selected from the group consisting of C 1-4 -alkyl, SO 2 R 3211 , SO 2 C 1-4 -alkyl, SO 2 C 7-11 -aralkyl,
- R 3311 , R 3312 and R 3313 is a radical selected from the group consisting of C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 7-11 aralkyl, C 2-4 alkenyl -Aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-
- R 3311 , R 3312 and R 3313 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R 4 is H, C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkylene-OH, C 2-6 -alkenyl, C 7-11 -aralkyl, C 2-4 -alkenyl-aryl, C 2-4 -alkynyl-aryl, C 1-4 -alkyl-hetaryl, C 2-4 -alkenyl-hetaryl, C 2-4 -alkynyl-hetaryl, C 2-6 -alkynyl, optionally substituted by Si (C 1 -4- alkyl) 3 , or R 4 is a radical selected from the group consisting of aryl, het, hetaryl and optionally substituted by C 14 alkyl; R 5 is H or C 1-6 alkyl;
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, het, aryl, hetaryl optionally substituted with one or more R 6 1 ;
- R 6 1 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 7 is H, C 1-4 alkyl, (CH 2 ) 2 _ 4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl; and pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is a radical selected from the group consisting of aryl, Cy.-n-aralkyl and
- Hetaryl which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 1-6 haloalkyl, C 1 -6- alkylene-COOH, C 1-6 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SR 1 1 , SOR 1 1 , SO 2 R 1 1 , Het or hetaryl,
- R 1 1 OH C 1-6 alkyl, C 2-6 alkenyl C 2-6 alkynyl, NR 1 1 1 R 1 1 2
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 31 , R 32 and R 33 ;
- R 31 is spiro or het, where Het may be optionally substituted with one or more R 311 ;
- R 311 is C 1-6 alkyl, C 2-6 alkenyl, OH, C 1-4 alkylene-OH, C 1-4 alkylene NR 3111 R 3112 , COR 3111 , COOR 3111 , CONR 3111 R 3112 , NR 3111 R 3112, Het, hetaryl, NHCOR 3111
- R 3111 is a radical selected from the group consisting of H, C 1-4 alkyl, aryl and C 7-11 aralkyl; optionally substituted with a radical selected from the group consisting of halogen, OH and CN; R 3112 is H, C 1-4 alkyl;
- R 32 is a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or more R 321
- R 321 is C 1-6 alkyl, C 3-6 cycloalkyl, OH, -NR 3211 R 3212 , NHCOR 3213 or
- Het optionally substituted with one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , CH 2 -C 3-6 cycloalkyl and aryl;
- R 3211 H, C 1-4 alkyl or C 7-11 aralkyl
- R 3212 is H, C 1-4 alkyl or C 7-11 aralkyl; R 3212 aryl, C 7-11 aralkyl; or
- R 322 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , NHCOR 3221 , C 1-6 haloalkyl, CN, OR 3221 , SO 2 R 3221 , C 3-6 -cycloalkyl, CO-Het, C 2-4 -alkynyl-hetaryl, guanidine or a radical selected from the group consisting of Het, hetaryl and aryl, which is optionally substituted by one or more Radicals selected from the group halogen, C 1-6 -alkyl, CONR 3221 R 3222 , OH, imidazolidinone;
- R 3221 HoderC 1-6 alkyl, aryl, C 7 -i rAralkyl
- R 3222 is H or C 1-6 alkyl
- Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of NH-C 1-6 -alkyl-
- N is (C 1-6 alkyl) 2 or Het, wherein Het may optionally be substituted with a C 1-6 alkyl radical;
- H or a radical selected from the group consisting of C 1-6 alkyl, C 2-4 alkenyl, C 2-4 alkynyl and aryl which may be optionally substituted with one or more R 331 radicals;
- R 331 C 5-6 -cycloalkyl, C 5 - 6 cycloalkenyl, OR 3311, NR 3311 R 3312, CONR 3311 R 3312, 3311 COOR, COR NR 3311 3312, 3311 SOR, SO 2 R 3311, C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH,
- CN halogen or Het optionally substituted by one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , SO 2 C 1-4 alkyl, SO 2 C 7-11 aralkyl, CH 2 -C 3-6 -cycloalkyl and aryl;
- R 3311 , R 3312 and R 3313 is a radical selected from the group consisting of C 1-4 -alkyl, C 7-11 -aralkyl, C 1-4 -alkyl-hetaryl, C0C 1-4 -alkyl-hetaryl; or two of the groups R 33 1 1 , R 33 1 2 and R 33 1 3 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R b R 4 , OR 4 , -CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NR 5 COOR 4 , NR 5 CONR 4 R 5 or NR 5 SOR 4 ;
- R 4 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 -alkylene-OH, C 2-6 alkenyl, C 7-11 aralkyl, C 1 4 alkyl
- R 5 is H or C 1-6 alkyl
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 3-6 -cycloalkyl, het, aryl, hetaryl, optionally substituted by one or more radicals R 6 1 ;
- R 7 is H, C 1-4 alkyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 7 is H, C 1-4 alkyl, (CH 2 ) 2-4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl
- R 7 is 1 H 2 or C 1-6 alkyl
- R a is a radical selected from the group consisting of aryl and C 7-11 aralkyl, which may optionally be substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or hetaryl optionally substituted by one or more C 1-4 alkyl;
- R 1 is C 1-4 -alkyl, C 1-4 -haloalkyl, C 1-4 -alkylene-COOH, C 1-4 -alkoxy, halogen, OH, CN, COR 1 1 , OC 1-4 -haloalkyl, NO 2 or SO 2 R 1 1 ;
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 3 1 1 C 1-4 -alkyl, C 2-4 -alkenyl, OH, C 1-4 -alkylene-OH, CH 2 NEt 2 , COMe, COOH, CONH 2 , NH 2 , Het, hetaryl,
- R is a radical selected from the group consisting of C 3-6 -cycloalkyl, het, hetaryl and spiro which is optionally substituted by one or two
- R 32 is C 1-4 -alkyl, cyclopentyl, OH, -NR 32 1 1 R 3 2 1 2 or
- R 3211 is H, methyl or benzyl
- R 3212 is H, methyl or benzyl
- R 322 C 2-4 alkenyl, C 2-4 alkynyl, COOR 3221 , CONR 3221 R 3222 ,
- NR 3221 R 3222 NHCOR 3221 , C 1-4 haloalkyl, CN, OH, SO 2 R 3221 , C 3-6 cycloalkyl or a radical selected from the group consisting of
- R 3221 is H or methyl; R 3222 is H or methyl; or Aryl optionally substituted with one or two R 323
- R 323 is a radical selected from the group consisting of
- R 33 is H or a radical selected from the group consisting of C 1-6 -alkyl and aryl, which may optionally be substituted by one or more radicals R 331 ;
- R 331 C 5-6 -cycloalkyl, C 5 - 6 cycloalkenyl, OR 3311, NR 3311 R 3312, CONR 3311 R 3312, 3311 COOR, COR NR 3311 3312, 3311 SOR, SO 2 R 3311, C (NR 3311 R 3312 ) NR 3313 , NR 3311 CONR 3312 R 3313 , OH, CN, halogen or Het, optionally substituted by one or more radicals selected from the group consisting of C 1-4 alkyl, SO 2 R 3211 , SO 2 C 1- 4- alkyl, SO 2 C 7-11 -aralkyl,
- R 3311 , R 3312 and R 3313 are a radical selected from the group consisting of C 1-4 -alkyl, C 7-11 -aralkyl, C 1-4 -alkyl-hetaryl, COC 1-4 -alkyl-hetaryl;
- R b R 4 , CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NHCOOR 4 , NHCONR 4 R 5 or OH;
- R 4 is H, C 1-4 -alkyl, C 1-4 -alkylene-OH, C 2-4 -alkynyl, C 1-6 -haloalkyl, aryl, het, hetaryl,
- NHR 6 or a residue selected from the group consisting of
- R 6 is H, C 1-4 alkyl, C 3-6 cycloalkyl, C 7-11 aralkyl, aryl optionally substituted with SO 2 CH 3 ;
- R 7 is H, NR 71 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted by C 1-4 alkyl or CONH 2 , or a radical selected from the group consisting of
- R 71 is H, C 1-4 alkyl, (CH 2 ) 2 R 711 or COOButyl;
- R 72 is H, C 1-4 alkyl;
- R 7111 is H or C 1-6 alkyl; R 7112 H or C 1-6 alkyl; and pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is phenyl or benzyl, each optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or
- R 1 is methyl, ethyl, propyl, butyl, CF 3, CH 2 COOH, methoxy, F, Cl, Br, OH, CN, COR 1 1, OCF 3, NO 2 or SO 2 R 1 1;
- R 2 is methyl, methoxy, F, Cl or Br
- R 3 is a radical selected from the group consisting of wherein n is 0 or 1; m is 0 or 1; o 2;
- R 3 1 is a radical selected from the group consisting of
- R 3 1 1 which may optionally be substituted by one or more R 3 1 1 .
- R 3 1 1 methyl, ethyl, OH, CH 2 OH, CH 2 CH 2 OH, CH 2 NEt 2 , COMe, COOH, CONH 2 , NH 2 ,
- R 3211 is H, methyl or benzyl
- R 3212 is H, methyl or benzyl
- R 322 C CH 2 , C ⁇ CH, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 ,
- NHCOR 3221 CF 3, CN, OH, SO 2 R 3221 or a radical selected from the group consisting of
- R 3221 is H or methyl;
- R 3222 is H or methyl; or
- R is a radical selected from the group consisting of
- R 5 is H, methyl or ethyl
- R c is NH 2 or a radical selected from the group consisting of
- B bond methylene, ethylene, propylene or butynylene
- R 6 is H, phenyl optionally substituted with SO 2 CH 3 ;
- R 7 H NR 7 1 R 72 , OR 72 , SR 72 or a radical selected from the group consisting of
- R 7 is H, methyl, ethyl, (CH 2 ) 2 R 7 1 1 or COOButyl;
- R 72 is H, methyl or ethyl;
- B is methylene, propylene
- R 7 is H, NR 7 1 R 7 2 or 1 -imidazolyl
- R 7 is H or methyl
- R 72 is H or methyl
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; and pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 and R 3 ;
- R 1 is methyl, ethyl, propyl, CF 3 , methoxy, F, Cl or Br;
- R 3 is a remainder
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 and R 3 ;
- R 1 is methyl, ethyl, propyl, CF 3 , methoxy, F, Cl or Br;
- R 3 is a remainder
- R a , R b and R c have the abovementioned meaning, as well as pharmacologically acceptable salt, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or
- R 1 is methyl, ethyl, propyl, CF 3 , CH 2 COOH, methoxy, F, Cl, Br, CN, COR 1 1 or SO 2 R 11 ;
- R 1 1 OH, methyl, NH 2, NHMe, NMe 2, or
- R 2 is methyl, F, Cl or Br
- R 3 is a radical selected from the group consisting of
- R is a radical selected from the group consisting of
- R 3 1 may be the optionally substituted with one or more R, 3 1.
- R 3 1 1 methyl, OH, CH 2 OH, CH 2 CH 2 OH, CH 2 NEt 2 , COMe, COOH, CONH 2 ,
- R 3211 is H or methyl
- R 3212 is H or methyl
- R 322 C CH 2 , C ⁇ CH, COOR 3221 , CONR 3221 R 3222 , NR 3221 R 3222 , CN, OH or a radical selected from the group consisting of
- R 32 is 2 H or methyl; R 322 is 2 H or methyl; or
- R 3 23 is a radical selected from the group consisting of
- R 3 is H, methyl or ethyl
- R b CH 2 OCH 3 , COR 4 , COOH, COOCH 3 CONR 4 R 5 , NH 2, NHCOOR 4 or OH;
- R 4 is H, methyl, propyl, C 1 H 6, phenyl,
- R 5 is H or methyl
- B is methylene, propylene;
- R 7 is H, NR 7 1 R 72 or 1 -imidazolyl;
- R 7 is H or methyl
- R 72 is H or methyl
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or
- R 1 is methyl, CF 3 , methoxy, F, Cl, Br, COR 1 1 or SO 2 R 1 1 ;
- R 1 1 is OH, NH 2, NHMe or NMe 2;
- R 3 is a radical selected from the group consisting of
- R 3 1 is a radical selected from the group consisting of
- R 32 is a radical selected from the group consisting of
- R 3 2 1 is a radical selected from the group consisting of
- R 322 COOR 322 1 , CONR 3 22 1 R 3222 , 4-pyrdinyl or a radical selected from the group consisting of
- R 32 is 2 H or methyl; R 322 is 2 H or methyl; or
- R 33 is H, methyl or ethyl
- R b R 4 , CH 2 OCH 3 or OH;
- B is methylene, propylene
- R 7 is H or methyl
- R 72 is H or methyl
- R a , R b and R c have the abovementioned meaning, as well as pharmacologically acceptable salt, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is aryl optionally substituted with one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 are independently C 1-6 alkyl, C 1-6 haloalkyl, C 1 ⁇ -alkoxy, halogen, COR 1 1, SO 2 R 1 1, R 1 1 C 1-6 alkyl, NR 1 1 1 R 1 1 2
- R 1 1 1 and R 1 1 2 together form a five- or six-membered heterocyclic ring which may optionally be substituted by a radical selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- X is bond or C 1-4 alkylene
- R 3a is a radical, identical or different, selected from the group consisting of R 3 1 , R 32 and R 33 ;
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 3 1 1 1 H 1 C 1-4 alkyl
- R 3 1 1 2 H 1 C 1-4 alkyl
- R a is phenyl optionally substituted with one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ;
- R 1 and R 2 independently of one another are C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, halogen, COR 11 , SO 2 R 11 ,
- R 11 is methyl ethyl, propyl, NR 111 R 112
- R 111 is H, methyl ethyl, propyl;
- R 112 H, methyl ethyl, propyl;
- R 111 and R 112 together form a five- or six-membered heterocyclic ring which may optionally be substituted with one
- Residue selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 31 , R 32 and R 33 ;
- R 31 is spiro or het, where Het may be optionally substituted with one or more R 311 ;
- R 3111 H methyl ethyl, propyl
- R, 3112 H methyl ethyl, propyl
- R 71 is H, methyl, ethyl, (CH 2 ) 2 R 711 or COOButyl;
- R 72 is H, methyl or ethyl;
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 and R 2 ;
- R 1 is methyl, ethyl, propyl, CF 3 , F, Cl, COR 1 1 or SO 2 R 1 1 ;
- R 2 is methyl, F or Cl
- R 7 is H, methyl, ethyl, (CH 2 ) 2 R 7 1 1 or COOButyl;
- R 72 is H, methyl or ethyl;
- R a is phenyl optionally substituted with R 1 ;
- R 1 is methyl, F, Cl, Br or COR 1 1 ;
- R 7 is H or methyl; :> 7 2 methyl;
- R a , R b and R c have the abovementioned meaning, as well as pharmacologically acceptable salt, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is aryl optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 , or hetaryl;
- R 1 and R 2 independently of one another are C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, halogen, COR 1 1 ;
- R 1 1 OH C 1-6 alkyl, NR 1 1 1 R 1 1 2
- R 3a is a radical, identical or different, selected from the group consisting of R 3 1 , R 32 and R 33 ;
- R 3 is spiro or het, wherein Het may optionally be substituted with one or more R 3 1 1 ;
- R 3 1 1 1 H, C 1-4 alkyl
- R 3 1 1 2 H, C 1-4 alkyl
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 , pyrazolyl or pyridinyl; R 1 and R 2 independently of one another are C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkoxy, halogen, COR 11 ,
- R 11 is methyl ethyl, propyl, NR 111 R 112
- R 111 is H, methyl ethyl, propyl;
- R 112 H, methyl ethyl, propyl;
- R 111 and R 112 together form a five- or six-membered heterocyclic ring which may optionally be substituted with one
- Residue selected from the group consisting of methyl, ethyl, propyl;
- R 3 is a radical selected from the group consisting of
- R 3a is a radical, identical or different, selected from the group consisting of R 31 , R 32 and R 33 ;
- R 31 is spiro or het, where Het may be optionally substituted with one or more R 311 ;
- R 3111 H methyl ethyl, propyl
- R 3112 H methyl ethyl, propyl
- R b is R 4 or OH; H;
- R 7 H NR 7 1 R 7 2 or a radical selected from the group consisting of
- R 7 1 H methyl or (CH 2 ) 2 R 7 1 1 ;
- R 72 is H, methyl or ethyl
- R a is phenyl optionally substituted by one or more radicals selected from the group consisting of R and R; or
- R 1 is methyl, methoxy, Cl, OH or COR 11 ;
- R 11 is NH 2 , NHMe or NMe 2 ;
- R 2 is methoxy or Cl
- R b is R 4 or OH
- R 7 H NR 71 R 72 or a radical selected from the group consisting of
- R 71 is H, methyl or (CH 2 ) 2 R 711 ;
- R 72 is H, methyl or ethyl; R / ⁇ ⁇ NMe 2 ;
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 , R 2 and R 3 ; or
- R 1 is Cl or COR 1 1 ;
- R b is R 4 or OH
- R 7 H pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a , R b and R c have the abovementioned meaning, as well as pharmacologically acceptable salt, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 and R 3 ; or
- R 1 is methyl, F, Cl or Br
- R 3 is a radical selected from the group consisting of
- R 4 is a radical selected from the group consisting of
- R 7 H pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof.
- R a is phenyl, optionally substituted by one or more radicals selected from the group consisting of R 1 and R 3 ; or
- R 3 is a radical selected from the group consisting of
- R 33 is H; R 4
- R a is H, d-8 alkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 1-6 haloalkyl, COR 8, NR 9 R 10, NO 2, OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 alkyl-NH 2 , spiro or a radical selected from the group consisting of C 7-11 aralkyl, CH 2 -O-aryl and het which may be optionally substituted with one or more halogen, C 1-6 alkyl, CO-C 1-4 haloalkyl, C 1-4 alkyl-NH 2 or CH 2 NHCOOR 12 ;
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 , CONR 12 or C 1-6 alkyl optionally substituted with one or more COOH, N (C 1-6 alkyl) 2 or Het optionally substituted with one or more C 1-6 alkyl ; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, C 1-6 -alkyl, CO-C 1-6 -alkyl or C 2 . 6- alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is H, C 1-6 -alkyl
- R 4 , R 5 is H, C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkylene-OH, C 1-6 -alkenyl, dn-aralkyl, C 1-4 -alkenyl-aryl, C 1-4 -alkynyl-aryl, C 1-4 -alkyl-hetaryl, C 1-4 -alkenyl-hetaryl, C 1-4 -alkynyl-hetaryl, C 2-6 -alkynyl, optionally substituted by Si (C 1 4- alkyl) 3 , or R 4 is a radical selected from the group consisting of aryl, het, hetaryl and optionally substituted by C 1 4 -alkyl;
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- B bond C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; H or a radical selected from the group consisting of C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, het, aryl, hetaryl with one or more radicals R 6 1 ;
- R 6 1 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 7 is H, C 1-6 alkyl, (CH 2 ) 2 _ 4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 i 1 NR 7 1 1 1 R 7 1 1 2 Het or 1 -imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl
- R 7 is 1 H 2 or C 1-6 alkyl
- R a is H, C 1-6 alkyl, C 2-6 alkenyl, C 3 _ 8 cycloalkyl, C 3 _ 8 cycloalkenyl, C 1-6 haloalkyl, COR 8, NR 9 R 10, NO 2, OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 -alkyl-NH 2 , spiro or a radical selected from the group consisting of C 7-11 -aralkyl, CH 2 -O-aryl and Het which may optionally be substituted with one or more halo, C 1-6 alkyl, CO-C 1-4 haloalkyl, C 1-4 alkyl-NH 2 or CH 2 NHCOOR 12 ;
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 or C 1-4 alkyl optionally substituted with one or more COOH, N (C 1-4 alkyl) 2 or Het optionally substituted with one or more C 1-4 alkyl; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, C 1 6 -alkyl, CO-C 1-4 -alkyl or C 2 6 alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is C 1-6 alkyl
- R 4 is H, C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkylene-OH, C 2-6 -alkenyl, dn-aralkyl, C 2-4 -alkenyl-aryl, C 2- 4 -alkynyl-aryl, C 1-4 alkyl hetaryl, hetaryl-C 2-4 alkenyl, C 2-4 alkynyl-hetaryl, C 2-6 alkynyl, optionally substituted by Si (C 1 -C 4 alkyl ) 3 , or R 4 is a radical selected from the group consisting of aryl, Het,
- R 5 is H or C 1-6 alkyl
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 2-4 -alkenyl, C 2-4 -alkynyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, het, aryl, hetaryl optionally substituted with one or more R 6 1 ;
- R 6 1 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 7 is H, C 1-4 alkyl, (CH 2 ) 2 _ 4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl;
- R a is H, C 1-6 alkyl, C 2-6 alkenyl, C 3 _ 6 cycloalkyl, C 3 _ 6 cycloalkenyl, C 1-6 haloalkyl, COR 8, NR 9 R 10, NO 2, OR 8 , SR 11 , SOR 11 , SO 2 R 11 , NHCO-C 1-6 -alkyl-NH 2 , spiro or a radical selected from the group consisting of C 7-11 -aralkyl, CH 2 -O-aryl and Het which may optionally be substituted with one or more halo, C 1-6 alkyl, CO-C 1-4 haloalkyl, C 1-4 alkyl-NH 2 or CH 2 NHCOOR 12 ;
- R 8 is C 1-6 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl or aryl optionally substituted with one or more halo or C 1-4 alkyl;
- R 9 is H, COOR 12 or C 1-4 alkyl optionally substituted with one or more COOH, N (C 1-4 alkyl) 2 or Het optionally substituted with one or more C 1-4 alkyl; or R 9 is het optionally substituted with one or more C 1-4 alkyl;
- R 10 is H, C 1-6 -alkyl, CO-C 1-4 -alkyl or C 2-6 -alkynyl;
- R 11 is C 1-6 alkyl optionally substituted with one or more N (C 1-4 alkyl) 2 ;
- R 12 is C 1-6 alkyl
- R b R 4 , OR 4 , -CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NR 5 COOR 4 , NR 5 CONR 4 R 5 or NR 5 SOR 4 ;
- R 4 is H, C 1-8 -alkyl, C 1-6 -haloalkyl, C 1-6 -alkylene-OH, C 2-6 -alkenyl, C 7 _n-aralkyl, C 1-4 -alkyl-hetaryl, C 2 -6 alkynyl, optionally substituted with Si 3, or R 4 represents a radical selected from the group consisting of aryl, Het, hetaryl and optionally substituted with C 1-4 alkyl (C 1 4 alkyl.);
- R 5 is H or C 1-6 alkyl
- R 4 and R 5 together form a five, six or seven membered ring consisting of carbon atoms and optionally a heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R c NHR 6 or a radical selected from the group consisting of
- R 6 is H or a radical selected from the group consisting of C 1-4 -alkyl, C 3-6 -cycloalkyl, het, aryl, hetaryl, optionally substituted by one or more radicals R 6 1 ;
- R 6 1 is halogen, CF 3 , OH, CN, OMe, SO 2 (C 1-4 alkyl);
- R 7 is H, C 1-4 alkyl, C 3-6 cycloalkyl, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het optionally substituted with C 1-4 alkyl or CONH 2 ;
- R 7 is H, C 1-4 alkyl, (CH 2 ) 2 _ 4 R 7 1 1 or COOButyl;
- R 72 is H, C 1-6 -alkyl, optionally substituted with one or more OH;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1-imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl;
- R a is H, C 1-6 -AIkIyI, C 2-6 alkenyl, C 3 _ 6 cycloalkyl, CF 3, COR 8, NR 9 R 10, NO 2, S (O) n R 11, or a radical selected from the group consisting of
- R 8 is C 1-4 alkyl, C 3-6 cycloalkyl, NH 2 , furanyl or phenyl optionally substituted with one or more chloro;
- R 9 is H, COOR 12 or piperidino, optionally substituted with one or more CH 3, or a radical selected from the group consisting of C 1 4 alkyl, which may be optionally substituted with one or more COOH, NMe 2 or 4-methylpiperazine ;
- R 10 is H, C 1-4 alkyl, C 2-4 alkynyl or COCH 3 ;
- R 11 is C 1-4 -alkyl, optionally substituted by one or more NMe 2 , R 12 is C 1-4 alkyl;
- R b R 4 , CH 2 OR 4 , COR 4 , COOR 4 , CONR 4 R 5 , NH 2 , NHCOOR 4 , NHCONR 4 R 5 or OH;
- R 4 is H, C 1-4 -alkyl, C 1-4 -alkylene-OH, C 2-4 -alkynyl, C 1-6 -haloalkyl, aryl, het, hetaryl,
- R 5 is H or C 1-4 alkyl
- NHR 6 or a residue selected from the group consisting of
- R 6 is H, C 1-4 alkyl, C 3-6 cycloalkyl, C 7-11 aralkyl, aryl optionally substituted with SO 2 CH 3 ;
- R 7 is H, NR 7 1 R 72 , OR 72 , SR 72 , hetaryl, Het, optionally substituted by C 1-4 -alkyl or CONH 2 , or a radical selected from the group consisting of
- R 7 is H, C 1-4 alkyl, (CH 2 ) 2 R 7 1 1 or COOButyl;
- R 72 is H, C 1-4 alkyl;
- R 7 1 1 NR 7 1 1 1 R 7 1 1 2 Het or 1 -imidazolyl, 2- (N-ethylpyrollidine);
- R 7 1 1 1 is H or C 1-6 alkyl; R 7 is 1 H 2 or C 1-6 alkyl;
- R a is H, C 1-6 -alkyl, C 2-6 -alkenyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkenyl, CF 3 , COR 8 , NR 9 R 10 ,
- R 8 is C 1-4 alkyl, C 3-6 cycloalkyl, NH 2 , hetaryl, aryl, optionally substituted with one or more chlorine;
- R 9 is H, COOR 12 or Het, optionally substituted with one or more C 1-4 alkyl, or a radical selected from the group consisting of C 1-4 alkyl, which may be optionally substituted with one or more COOH,
- R 1 0 H, C 1-4 alkyl, C 2-4 alkynyl or COCH 3;
- R 11 is C 1-4 -alkyl, optionally substituted with one or more N (C 1-4 -alkyl) 2 ,
- R 12 is C 1-4 alkyl
- n 0 or 2;
- R b is H, OH or COOEt
- R c is NH 2 or NHCOR 13 ;
- R 13 is C 1-4 -alkyl, or NR 13 1 R 132 ,
- R 13 is H or C 1-4 alkyl
- R 132 is H or C 1-4 alkyl
- R a is H, C 1-6 -AIkIyI 1 C 2-6 alkenyl, C 3-6 cycloalkyl, CF 3, COR 8, NR 9 R 10, NO 2, S (O) n R 11, or a radical selected from the group consisting of
- R 8 is C 1-4 alkyl, C 3-6 cycloalkyl, NH 2 , furanyl or phenyl optionally substituted with one or more chloro;
- R 9 is H, COOR 12 or piperidino, optionally substituted by one or more CH 3 , or a radical selected from the group consisting of C 1-4 -alkyl, which may optionally be substituted by one or more COOH, NMe 2 or 4- methylpiperazine;
- R 10 is H, C 1-4 alkyl, C 2-4 alkynyl or COCH 3 ;
- R 11 is C 1-4 -alkyl, optionally substituted by one or more NMe 2 ,
- R 12 is C 1-4 alkyl
- R b is H, OH or COOEt;
- R c is NH 2 or NHCOR 13 ;
- R 13 is C 1-4 -alkyl, or NR 13 1 R 13 2 ,
- R 13 is H or C 1-4 alkyl;
- R 132 is H or C 1-4 alkyl;
- R a is H, methyl, ethyl, propyl, butyl, 3-methyl-butyl, propenyl, cyclopropyl, cyclohexyl,
- R 8 is methyl, propyl, cyclopropyl, NH 2 , furanyl or phenyl optionally substituted with one or more chloro;
- R 9 is H, COOR 12 or piperidino, optionally substituted with one or more CH 3, or a radical selected from the group consisting of methyl, ethyl and propyl, which may be optionally substituted with one or more COOH, NMe 2 or 4-methylpiperazine ;
- R 10 is H, methyl, COCH 3 , C ⁇ CH or CH 2 C ⁇ CH;
- R 11 is ethyl or propyl, optionally substituted by one or more NMe 2 ,
- R b is H, OH or COOEt
- R c is NH 2 or NHCOR 13 ;
- R 13 is methyl or NR 13 1 R 132 ,
- R a is Propyl, COR 8 , NR 9 R 10 , S (O) n R 11 and
- R 9 is methyl
- R 10 is methyl
- R b is H or OH
- R c is NH 2 or NHCOCH 3 ;
- C 1-6 -alkyl (including those which are part of other groups) is understood to mean branched and unbranched alkyl groups having 1 to 6 carbon atoms and branched and unbranched alkyl groups having 1 to 10 by the term "C 1-4 -alkyl” 4 carbon atoms understood. Preference is given to alkyl groups having 1 to 4 carbon atoms. Examples include: methyl, ethyl, n-propyl, / so-propyl, n-butyl, / so-butyl, sec-butyl, terf-butyl, n-pentyl, / so-pentyl, neo-pentyl or hexyl.
- the abbreviations Me, Et, n-Pr, / -Pr, n-Bu, / -Bu, t-Bu, etc. are also used for the abovementioned groups.
- the definitions of propyl, butyl, pentyl and hexyl include all conceivable isomeric forms of the respective radicals.
- propyl includes n-propyl and / so-propyl
- butyl includes / so-butyl, sec-butyl and tert-butyl, etc.
- C 1-6 -alkylene (including those which are part of other radicals) are to be understood as meaning branched and unbranched alkylene groups having 1 to 6 carbon atoms and branched and unbranched alkylene groups having 1 to 10 by the term “C 1-4 -alkylene” 4 carbon atoms understood. Preference is given to alkylene groups having 1 to 4
- Carbon atoms include: methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene, Pentylene, 1, 1-dimethylpropylene, 2,2, -dimethylpropylene, 1, 2-dimethylpropylene, 1, 3-dimethylpropylene or hexylene.
- propylene, butylene, pentylene and hexylene include all conceivable isomeric forms of the respective radicals of the same carbon number.
- propyl also includes 1-methylethylene and butylene includes 1-methylpropylene, 1, 1-dimethylethylene, 1, 2-dimethylethylene.
- C 2-6 alkenyl (including those which are part of other radicals) are branched and unbranched alkenyl groups having 2 to 6 carbon atoms and the term “C 2-4 alkenyl” branched and unbranched alkenyl groups having 2 to 4 Carbon atoms understood, as far as they have at least one double bond.
- alkenyl groups having 2 to 4 carbon atoms examples include: ethenyl or vinyl, propenyl, butenyl, pentenyl, or hexenyl. Unless otherwise described, the definitions propenyl, butenyl, pentenyl and hexenyl include all conceivable isomeric forms of the respective radicals.
- propenyl includes 1-propenyl and 2-propenyl
- butenyl includes 1-, 2- and 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, etc.
- C 2-6 alkenylene (including those which are part of other radicals) is understood as meaning branched and unbranched alkenylene groups having 2 to 6 carbon atoms and branched and unbranched alkylene groups having 2 to 6 under the term "C 2-4 alkenylene” 4 carbon atoms understood. Alkenylene groups having 2 to 4 carbon atoms are preferred.
- Examples include: ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1, 1 - dimethylethenylene, 1, 2-dimethylethenylene, pentenylene, 1, 1-dimethylpropenylene, 2,2, - dimethylpropenylene, 1, 2- Dimethylpropenylene, 1, 3-dimethylpropenylene or hexenylene.
- propenylene, butenylene, pentenylene and hexenylene include all conceivable isomeric forms of the respective radicals of equal carbon number.
- propenyl also includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 1, 1-dimethylethenylene, 1, 2-dimethylethenylene.
- C 2-6 -alkynyl (including those which are part of other radicals) are branched and unbranched alkynyl groups having 2 to 6 carbon atoms and under the term “C 2-4 alkynyl” means branched and unbranched alkynyl groups having 2 to 4 carbon atoms, provided they have at least one triple bond. Preferred are alkynyl groups having 2 to 4 carbon atoms. Examples include: ethynyl, propynyl, butynyl, pentynyl, or hexynyl.
- propynyl includes 1-propynyl and 2-propynyl
- butinyl includes 1-, 2- and 3-butynyl, 1-methyl-1-propynyl, 1-methyl-2-propynyl, etc.
- C 2-6 -alkynylene (even if they are part of other groups) are branched and unbranched alkynylene groups having 2 to 6 carbon atoms and the term “C 2-4 -alkynylene” branched and unbranched alkylene groups having 2 to 4 carbon atoms understood. Alkynylene groups having 2 to 4 carbon atoms are preferred. Examples include: ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1, 1 -
- the definitions propynylene, butynylene, pentynylene and hexynylene include all conceivable isomeric forms of the respective radicals of the same carbon number.
- propynyl also includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 1, 1-dimethylethynylene, 1, 2-dimethylethynylene.
- C 1 ⁇ -alkoxy (even if they are part of other radicals) are branched and unbranched alkoxy groups having 1 to 6 carbon atoms and the term "C 1-4 alkoxy” branched and unbranched alkoxy groups having 1 to 4 Understood carbon atoms. Preferred are alkoxy groups having 1 to 4 carbon atoms. Examples include: methoxy, ethoxy, propoxy, butoxy or pentoxy. If appropriate, the abbreviations OMe, OEt, OPr, etc. are also used for the abovementioned groups. Unless otherwise stated, the definitions of propoxy, butoxy and pentoxy include all conceivable isomeric forms of the respective radicals.
- propoxy includes n-propoxy and / so-propoxy, butoxy includes / so-butoxy, sec-butoxy and terf-butoxy, etc.
- C 3-8 -cycloalkyl (including those which are part of other groups) cyclic alkyl groups having 3 to 8 carbon atoms are understood, cyclic, the term “C 3-6 cycloalkyl” are alkyl groups having 3 to 8 carbon atoms and the term "C 5, 6 -cycloalkyl” means cyclic alkyl groups having 5 to 6 carbon atoms. Examples include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
- C 3-6 -cycloalkenyl means cyclic alkyl groups having 5 or 6 carbon atoms which contain one or two double bonds. Examples include: cyclopentenyl, cyclopentadienyl, cyclohexenyl or cyclohexadienyl.
- C 1-6 haloalkyl (including those which are part of other radicals) are understood as meaning branched and unbranched alkyl groups having 1 to 6 carbon atoms in which one or more hydrogen atoms are selected from the group consisting of fluorine, chlorine or bromine by a halogen atom , preferably fluorine and chlorine, particularly preferably fluorine are exchanged.
- C 1-4 -haloalkyl means correspondingly branched and unbranched alkyl groups having 1 to 4 carbon atoms, in which one or more hydrogen atoms have been exchanged analogously as described above.
- C 1-4 haloalkyl For example: CH 2 F, CHF 2 , CF 3 ,
- C 7-11 -aralkyl (including those which are part of other groups) means branched and unbranched alkyl groups having 1 to 4 carbon atoms which are substituted by an aromatic ring system having 6 carbon atoms.
- aromatics may be substituted with one or more radicals selected from the group consisting of methyl, ethyl, / so-propyl, tert-butyl, hydroxy, fluorine, chlorine, bromine and iodine.
- aryl (even if they are part of other radicals) are understood as meaning aromatic ring systems having 6 or 10 carbon atoms. For example: phenyl or naphthyl, more preferably aryl is phenyl.
- heterocyclic rings (“Het”) is understood as meaning five-, six- or seven-membered, saturated or unsaturated heterocyclic rings or 5-10-membered, bicyclic hetero rings, the one, two or three heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen In this case, the ring may be linked to the molecule via a carbon atom or, if present, via a nitrogen atom.
- heterocyclic rings As examples of five-, six- or seven-membered, saturated or unsaturated heterocyclic rings, mention is made:
- a heterocyclic ring may be provided with a keto group. As an example for this are called.
- pyrrolizine indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine,
- heterocyclic rings include, the term heterocyclic aromatic defines five- or six-membered heterocyclic aromatic or 5-10 membered, bicyclic Hetarylringe the one, two or three heteroatoms selected from the group can contain oxygen, sulfur and nitrogen, and contain as many conjugated double bonds that an aromatic system is formed.
- the ring may be linked to the molecule via a carbon atom or, if present, via a nitrogen atom.
- five- or six-membered heterocyclic aromatic compounds there are mentioned:
- Examples of 5-10 membered bicyclic hetaryl rings include pyrrolizine, indole, indolizine, isoindole, indazole, purine, quinoline, isoquinoline, benzimidazole, benzofuran, benzopyran, benzothiazole, benzothiazole, benzoisothiazole, pyridopyrimidine, pteridine, pyrimidopyrimidine.
- heterocyclic spiro rings is understood to mean 5-10 membered spirocyclic rings which may optionally contain one, two or three heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, in which case the ring may have a carbon atom or, if present be linked to the molecule via a nitrogen atom. Unless otherwise stated, a spirocyclic ring may be provided with a keto group. As examples are mentioned:
- the term "optionally substituted” is understood to mean the abovementioned group which is optionally substituted by a lower-molecular radical.
- Low-molecular radicals are understood to be chemically meaningful groups consisting of 1-200 atoms. Preferably, such groups have no negative effect on the pharmacological activity of the compounds.
- the groups may include:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0516557-1A BRPI0516557A (pt) | 2004-10-07 | 2005-10-05 | pi3 cinases |
CA2579279A CA2579279C (en) | 2004-10-07 | 2005-10-05 | Tricyclic thiazole derivatives as pi3 kinases |
JP2007535159A JP5122287B2 (ja) | 2004-10-07 | 2005-10-05 | Pi3キナーゼ |
MX2007004051A MX2007004051A (es) | 2004-10-07 | 2005-10-05 | Pi3-quinasas. |
CNA2005800344060A CN101048418A (zh) | 2004-10-07 | 2005-10-05 | Pi3-激酶 |
EP05805652A EP1802636B1 (de) | 2004-10-07 | 2005-10-05 | Pi3-kinasen inhibitoren |
AU2005293607A AU2005293607A1 (en) | 2004-10-07 | 2005-10-05 | PI3 kinases |
IL182398A IL182398A0 (en) | 2004-10-07 | 2007-04-10 | Pi3 kinases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004048877.0 | 2004-10-07 | ||
DE102004048877A DE102004048877A1 (de) | 2004-10-07 | 2004-10-07 | PI3-Kinasen |
DE102005005813.2 | 2005-02-09 | ||
DE102005005813A DE102005005813A1 (de) | 2005-02-09 | 2005-02-09 | PI3-Kinasen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006040279A1 true WO2006040279A1 (de) | 2006-04-20 |
Family
ID=35583390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/055015 WO2006040279A1 (de) | 2004-10-07 | 2005-10-05 | Pi3-kinasen |
Country Status (14)
Country | Link |
---|---|
US (4) | US7691888B2 (de) |
EP (2) | EP2343303A1 (de) |
JP (1) | JP5122287B2 (de) |
KR (1) | KR20070064660A (de) |
CN (1) | CN101048418A (de) |
AR (1) | AR055273A1 (de) |
AU (1) | AU2005293607A1 (de) |
BR (1) | BRPI0516557A (de) |
CA (1) | CA2579279C (de) |
IL (1) | IL182398A0 (de) |
MX (1) | MX2007004051A (de) |
RU (2) | RU2403258C2 (de) |
TW (1) | TW200628475A (de) |
WO (1) | WO2006040279A1 (de) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007115931A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren |
WO2007115930A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazole |
WO2007115932A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-chinazoline |
WO2007115933A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazole |
WO2007115929A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
EP1878731A1 (de) * | 2006-06-26 | 2008-01-16 | Helm AG | Verfahren zur Herstellung von Pramipexole |
WO2009112565A1 (en) * | 2008-03-13 | 2009-09-17 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles |
WO2009120826A1 (en) * | 2008-03-27 | 2009-10-01 | Wyeth | 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof |
WO2009123971A1 (en) * | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
JP2010504913A (ja) * | 2006-09-26 | 2010-02-18 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連使用のための縮合環化合物 |
JP2010505807A (ja) * | 2006-10-04 | 2010-02-25 | アーク・セラピューティックス・リミテッド | Np−1アンタゴニスト活性を有するアルギニン誘導体 |
WO2010043676A1 (en) * | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
WO2010079238A1 (en) | 2009-01-12 | 2010-07-15 | Addex Pharma S.A. | Heterotricyclic compounds as positive allosteric modulators of metabotropic glutamate receptors |
WO2010115836A1 (en) | 2009-04-08 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Substituted piperidines as ccr3 antagonists |
WO2010122091A1 (en) | 2009-04-22 | 2010-10-28 | Boehringer Ingelheim International Gmbh | Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer |
WO2010122071A1 (en) | 2009-04-22 | 2010-10-28 | Boehringer Ingelheim International Gmbh | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer |
JP2011509261A (ja) * | 2008-01-07 | 2011-03-24 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途向けの化合物 |
WO2012009000A2 (en) * | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
WO2012009001A3 (en) * | 2010-07-14 | 2012-03-15 | Addex Pharma S.A. | Novel tetrahydropyrazolo[3,4-b]azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
WO2012101184A1 (en) | 2011-01-26 | 2012-08-02 | Boehringer Ingelheim International Gmbh | New 5-alkynyl-pyridines |
WO2012101186A1 (en) | 2011-01-26 | 2012-08-02 | Boehringer Ingelheim International Gmbh | New 5-alkynyl-pyridines |
EP2546249A1 (de) | 2011-07-15 | 2013-01-16 | Boehringer Ingelheim International Gmbh | 5-Alkynylpyridine |
JP5258563B2 (ja) * | 2006-06-29 | 2013-08-07 | 日産化学工業株式会社 | αアミノ酸誘導体及びそれを有効成分として含む医薬 |
US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050096332A1 (en) * | 2003-10-30 | 2005-05-05 | Boehringer Ingelheim International Gmbh | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
CA2579279C (en) * | 2004-10-07 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Tricyclic thiazole derivatives as pi3 kinases |
CN101443335A (zh) * | 2006-04-06 | 2009-05-27 | 贝林格尔.英格海姆国际有限公司 | 噻唑基-二氢-吲唑 |
WO2009039140A1 (en) * | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
CN102089303A (zh) * | 2008-07-17 | 2011-06-08 | 旭化成制药株式会社 | 含氮杂环化合物 |
WO2010024258A1 (ja) * | 2008-08-29 | 2010-03-04 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環アゾール誘導体 |
UY32748A (es) * | 2009-07-02 | 2011-01-31 | Novartis Ag | 2-carboxamida-cicloamino-ureas |
GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US8263633B2 (en) | 2009-09-28 | 2012-09-11 | F. Hoffman-La Roche Ag | Benzoxepin PI3K inhibitor compounds and methods of use |
ES2444779T3 (es) | 2009-09-28 | 2014-02-26 | F. Hoffmann-La Roche Ag | Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer |
US9073940B2 (en) | 2009-11-13 | 2015-07-07 | Merck Serono Sa | Tricyclic pyrazol amine derivatives |
CN103153062B (zh) | 2010-05-24 | 2015-07-15 | 因特利凯有限责任公司 | 杂环化合物及其用途 |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
EP2688891B1 (de) | 2011-03-21 | 2017-11-15 | F. Hoffmann-La Roche AG | Für pi3k p110 delta selektive benzoxazepinverbindungen und verwendungsverfahren |
KR20140129120A (ko) * | 2012-02-06 | 2014-11-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 기침 치료용 pi3k 저해제 |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057008A1 (en) * | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
US20020151544A1 (en) * | 2000-04-27 | 2002-10-17 | Masahiko Hayakawa | Fused heteroaryl derivatives |
WO2003072557A1 (en) * | 2002-02-28 | 2003-09-04 | Novartis Ag | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
WO2005005438A1 (en) * | 2003-07-08 | 2005-01-20 | Cyclacel Limited | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5533405A (en) | 1978-08-29 | 1980-03-08 | Teijin Ltd | Hexahydronaphtho(1',2':4,5)imidazo(2,1-b)thiazole and its preparation |
WO1979001080A1 (en) | 1978-05-17 | 1979-12-13 | Teijin Ltd | Hexahydronaphtoimidazothiazoles and process for preparing same |
EP0186087B1 (de) | 1984-12-22 | 1989-08-23 | Dr. Karl Thomae GmbH | Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel |
US5358949A (en) * | 1986-03-05 | 1994-10-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives |
US5182290A (en) * | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
TW260664B (de) * | 1993-02-15 | 1995-10-21 | Otsuka Pharma Factory Inc | |
JP3670309B2 (ja) | 1993-04-01 | 2005-07-13 | 第一製薬株式会社 | 二環性複素環化合物 |
NO941135L (no) | 1993-04-01 | 1994-10-03 | Daiichi Seiyaku Co | Tiazolpyrimidin derivater |
AU727654B2 (en) * | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
GB2361236B (en) | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
KR100423899B1 (ko) | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
AU2002349912A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
EP1349179A1 (de) | 2002-03-18 | 2003-10-01 | ATOFINA Research | Leitfähige Polyolefine mit guten mechanischen Eigenschaften |
BR0312752A (pt) | 2002-07-10 | 2005-04-26 | Applied Research Systems | Derivados de benzeno fundido de azolidinona-vinil |
JP4790266B2 (ja) | 2002-09-30 | 2011-10-12 | バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト | 縮合アゾールピリミジン誘導体 |
AU2003280188A1 (en) | 2002-12-06 | 2004-06-30 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
BR0317572A (pt) | 2002-12-20 | 2005-11-22 | Warner Lambert Co | Benzoxazinas e seus derivados como inibidores de pi3ks |
NO20041733L (no) * | 2004-04-28 | 2005-10-31 | Thin Film Electronics Asa | Organisk elektronisk krets med funksjonelt mellomsjikt og fremgangsmate til dens fremstilling. |
CA2579279C (en) | 2004-10-07 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Tricyclic thiazole derivatives as pi3 kinases |
FR2887993B1 (fr) * | 2005-07-01 | 2007-08-03 | Commissariat Energie Atomique | Dispositif de detection de rayonnements a electrodes empilees et methode de detection de rayonnements ionisants mettant en oeuvre un tel dispositif |
US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
CA2647278A1 (en) * | 2006-04-06 | 2007-10-11 | Boehringer Ingelheim International Gmbh | Thiazolyldihydroindazole derivatives as protein kinase inhibitors |
-
2005
- 2005-10-05 CA CA2579279A patent/CA2579279C/en active Active
- 2005-10-05 CN CNA2005800344060A patent/CN101048418A/zh active Pending
- 2005-10-05 BR BRPI0516557-1A patent/BRPI0516557A/pt not_active IP Right Cessation
- 2005-10-05 WO PCT/EP2005/055015 patent/WO2006040279A1/de active Application Filing
- 2005-10-05 EP EP11158787A patent/EP2343303A1/de not_active Withdrawn
- 2005-10-05 JP JP2007535159A patent/JP5122287B2/ja active Active
- 2005-10-05 AU AU2005293607A patent/AU2005293607A1/en not_active Abandoned
- 2005-10-05 MX MX2007004051A patent/MX2007004051A/es not_active Application Discontinuation
- 2005-10-05 RU RU2007116858/04A patent/RU2403258C2/ru not_active IP Right Cessation
- 2005-10-05 RU RU2007116861/04A patent/RU2007116861A/ru not_active Application Discontinuation
- 2005-10-05 US US11/243,796 patent/US7691888B2/en active Active
- 2005-10-05 KR KR1020077010387A patent/KR20070064660A/ko not_active Application Discontinuation
- 2005-10-05 EP EP05805652A patent/EP1802636B1/de active Active
- 2005-10-05 US US11/244,299 patent/US20060106013A1/en not_active Abandoned
- 2005-10-06 TW TW094134899A patent/TW200628475A/zh unknown
- 2005-10-07 AR ARP050104225A patent/AR055273A1/es unknown
-
2007
- 2007-04-10 IL IL182398A patent/IL182398A0/en unknown
-
2009
- 2009-02-05 US US12/366,248 patent/US8232286B2/en active Active
-
2010
- 2010-01-11 US US12/685,213 patent/US8207349B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057008A1 (en) * | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
US20020151544A1 (en) * | 2000-04-27 | 2002-10-17 | Masahiko Hayakawa | Fused heteroaryl derivatives |
WO2003072557A1 (en) * | 2002-02-28 | 2003-09-04 | Novartis Ag | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
WO2005005438A1 (en) * | 2003-07-08 | 2005-01-20 | Cyclacel Limited | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases |
Non-Patent Citations (3)
Title |
---|
BULLETIN OF THE COLLEGE OF SCIENCE, vol. 12-13, 1973, pages 91-97 * |
CHORDIA M D ET AL: "2-Aminothiazoles: A new class of agonist allosteric enhancers of A1 Adenosine receptors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 12, 2002, pages 1563 - 1566, XP002352852, ISSN: 0960-894X * |
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ALAZAWE S ET AL: "Preparation of substituted 2-aminothiazoles", XP002364167, retrieved from STN accession no. 1976:421193 Database accession no. 85:8521193 * |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7691868B2 (en) | 2006-04-06 | 2010-04-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
WO2007115931A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren |
AU2007236043B2 (en) * | 2006-04-06 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydroquinazolines |
WO2007115933A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazole |
WO2007115929A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline |
WO2007115930A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazole |
US7517995B2 (en) | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
US8334378B2 (en) | 2006-04-06 | 2012-12-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same |
WO2007115932A1 (de) * | 2006-04-06 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-chinazoline |
EP1878731A1 (de) * | 2006-06-26 | 2008-01-16 | Helm AG | Verfahren zur Herstellung von Pramipexole |
JP5258563B2 (ja) * | 2006-06-29 | 2013-08-07 | 日産化学工業株式会社 | αアミノ酸誘導体及びそれを有効成分として含む医薬 |
JP2010504913A (ja) * | 2006-09-26 | 2010-02-18 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連使用のための縮合環化合物 |
US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
JP2010505807A (ja) * | 2006-10-04 | 2010-02-25 | アーク・セラピューティックス・リミテッド | Np−1アンタゴニスト活性を有するアルギニン誘導体 |
US8227606B2 (en) | 2006-10-04 | 2012-07-24 | Ark Therapeutics, Ltd. | Arginine derivatives with NP-1 antagonistic activity |
JP2011509261A (ja) * | 2008-01-07 | 2011-03-24 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途向けの化合物 |
WO2009112565A1 (en) * | 2008-03-13 | 2009-09-17 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles |
US8304556B2 (en) | 2008-03-13 | 2012-11-06 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles |
WO2009120826A1 (en) * | 2008-03-27 | 2009-10-01 | Wyeth | 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof |
RU2506267C2 (ru) * | 2008-03-31 | 2014-02-10 | Дженентек, Инк. | Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение |
US8846762B2 (en) | 2008-03-31 | 2014-09-30 | Genentech, Inc. | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use |
KR101626996B1 (ko) | 2008-03-31 | 2016-06-02 | 제넨테크, 인크. | 벤조피란 및 벤족세핀 pi3k 저해제 화합물 및 이의 사용 방법 |
US9309265B2 (en) | 2008-03-31 | 2016-04-12 | Genentech, Inc. | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use |
WO2009123971A1 (en) * | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
KR20100137551A (ko) * | 2008-03-31 | 2010-12-30 | 제넨테크, 인크. | 벤조피란 및 벤족세핀 pi3k 저해제 화합물 및 이의 사용 방법 |
US8399690B2 (en) | 2008-03-31 | 2013-03-19 | Genentech, Inc. | 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds |
JP2012505857A (ja) * | 2008-10-17 | 2012-03-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホスファチジルイノシトール−3−キナーゼ(pi−3キナーゼ)阻害剤としてのテトラ−アザ−複素環 |
US8653097B2 (en) | 2008-10-17 | 2014-02-18 | Boehringer Ingelheim International Gmbh | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor |
WO2010043676A1 (en) * | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
WO2010079238A1 (en) | 2009-01-12 | 2010-07-15 | Addex Pharma S.A. | Heterotricyclic compounds as positive allosteric modulators of metabotropic glutamate receptors |
US8697744B2 (en) | 2009-01-12 | 2014-04-15 | Addex Pharma S.A. | Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors |
WO2010115836A1 (en) | 2009-04-08 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Substituted piperidines as ccr3 antagonists |
US8288379B2 (en) | 2009-04-22 | 2012-10-16 | Boehringer Ingelheim International Gmbh | Thia-triaza-cyclopentazulenes |
WO2010122071A1 (en) | 2009-04-22 | 2010-10-28 | Boehringer Ingelheim International Gmbh | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer |
US9243000B2 (en) | 2009-04-22 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Thia-triaza-indacenes |
US20110112087A1 (en) * | 2009-04-22 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Thia-triaza-cyclopentazulenes |
WO2010122091A1 (en) | 2009-04-22 | 2010-10-28 | Boehringer Ingelheim International Gmbh | Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer |
JP2012524751A (ja) * | 2009-04-22 | 2012-10-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療用pi3−キナーゼ阻害薬としてのチア−トリアザ−シクロペンタアズレン |
JP2012524756A (ja) * | 2009-04-22 | 2012-10-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の治療用PI3−キナーゼ阻害薬としてのチア−トリアザ−as−インダセン |
WO2012009001A3 (en) * | 2010-07-14 | 2012-03-15 | Addex Pharma S.A. | Novel tetrahydropyrazolo[3,4-b]azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
WO2012009000A3 (en) * | 2010-07-14 | 2013-04-18 | Addex Pharma S.A. | Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
WO2012009000A2 (en) * | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Novel fused pyrazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US9765091B2 (en) | 2010-07-14 | 2017-09-19 | Addex Pharma S.A. | Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
WO2012101186A1 (en) | 2011-01-26 | 2012-08-02 | Boehringer Ingelheim International Gmbh | New 5-alkynyl-pyridines |
WO2012101184A1 (en) | 2011-01-26 | 2012-08-02 | Boehringer Ingelheim International Gmbh | New 5-alkynyl-pyridines |
EP2546249A1 (de) | 2011-07-15 | 2013-01-16 | Boehringer Ingelheim International Gmbh | 5-Alkynylpyridine |
US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
US11702421B2 (en) | 2018-12-31 | 2023-07-18 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11845753B2 (en) | 2018-12-31 | 2023-12-19 | Biomea Fusion, Inc. | Inhibitors of menin-mll interaction |
US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
Also Published As
Publication number | Publication date |
---|---|
BRPI0516557A (pt) | 2008-09-09 |
US8232286B2 (en) | 2012-07-31 |
JP5122287B2 (ja) | 2013-01-16 |
US20060100254A1 (en) | 2006-05-11 |
US20090156554A1 (en) | 2009-06-18 |
EP2343303A1 (de) | 2011-07-13 |
CA2579279A1 (en) | 2006-04-20 |
EP1802636A1 (de) | 2007-07-04 |
EP1802636B1 (de) | 2013-03-27 |
US8207349B2 (en) | 2012-06-26 |
RU2403258C2 (ru) | 2010-11-10 |
JP2008515852A (ja) | 2008-05-15 |
AU2005293607A1 (en) | 2006-04-20 |
IL182398A0 (en) | 2007-07-24 |
US7691888B2 (en) | 2010-04-06 |
RU2007116858A (ru) | 2008-12-27 |
CN101048418A (zh) | 2007-10-03 |
TW200628475A (en) | 2006-08-16 |
RU2007116861A (ru) | 2009-03-20 |
US20100113414A1 (en) | 2010-05-06 |
KR20070064660A (ko) | 2007-06-21 |
MX2007004051A (es) | 2007-05-24 |
CA2579279C (en) | 2013-10-01 |
AR055273A1 (es) | 2007-08-15 |
US20060106013A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006040279A1 (de) | Pi3-kinasen | |
US7517995B2 (en) | Thiazolyl-dihydro-cyclopentapyrazole | |
JP5237262B2 (ja) | チアゾリル−ジヒドロキナゾリン | |
WO2007115933A1 (de) | Thiazolyl-dihydro-indazole | |
WO2007115930A1 (de) | Thiazolyl-dihydro-indazole | |
EP2018385B1 (de) | Thiazolyl-dihydro-quinazoline | |
DE102004048877A1 (de) | PI3-Kinasen | |
DE102005005813A1 (de) | PI3-Kinasen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200701470 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2579279 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005805652 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1958/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/004051 Country of ref document: MX Ref document number: 2005293607 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500740 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 554364 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007535159 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580034406.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182398 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005293607 Country of ref document: AU Date of ref document: 20051005 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005293607 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007116861 Country of ref document: RU Ref document number: 1020077010387 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005805652 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0516557 Country of ref document: BR |